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Sphingolipids have over the years, been explored as cancer therapy targets. 
FTY720 (Fingolimod, Gilenya) is a sphingosine analogue drug used for the treatment of 
multiple sclerosis. FTY720 is phosphorylated by sphingosine kinase 2, to generate P- 
FTY720 to exert its immunosuppressive properties through binding to sphingosine -1 
phosphate receptors (S1PRs). FTY720 also exhibits anti-cancer properties. Our previous 
studies indicated that FTY720’s anti-cancer property is through induction of necroptosis. 
FTY720 directly binds to I2PP2A/SET (Inhibitor 2 of PP2A), consequently activating the 
tumor suppressor protein phosphatase 2A (PP2A). The activated PP2A then induces cell 
death by activating Receptor-Interacting Protein kinase-1 (RIPK1), involved in 
necroptosis signaling. Little is known about the roles of FTY720 in ceramide signaling 
and regulation of necroptosis in lung cancer. We therefore, sought to investigate the 
mechanisms of FTY720 in inducing necroptosis with regard to ceramide signaling. Our 
data indicate that C16-ceramide is crucial for FTY720-induced cell death. Interestingly, 
FTY720 does not induce ceramide generation but leads to the formation of specific 
ceramide-multi-protein complexes at the plasma membrane involved in plasma 
membrane disruption and necroptosis. Here we show D147, N148 and N169 residues in 
RIPK1 are important for RIPK1- ceramide binding and cell death. In addition, we show a 
novel role for non-muscle Myosin IIA (NMIIA) in trafficking these complexes to the 
plasma membrane to promote membrane rupture. We identify RIPK1 L112 and C256 
residues as critical for RIPK1-NMIIA interaction. We hereby propose that these novel 
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ceramide complexes form non-selective pores supported by RIPK1 and NMIIA. Our data 
suggest that these structures are very specific and are important in the execution of 
necroptosis independent of RIPK3 and MLKL. Additionally, preliminary data suggest 
that these novel structures can also form in-vivo, without external stimulus, indicating a 



















1.  Sphingolipids metabolism 
	
Sphingolipids are a class of structural lipids that are found in membranes. In 
addition to their structural role, some sphingolipids have been shown to play key roles in 
signal transduction in cells 1. These bioactive sphingolipids like ceramide, sphingosine 
and sphingosine 1 phosphate (S1P) have been shown to have roles in cell death, cell 
proliferation, cell migration and inflammation. Studies have indicated that ceramide and 
S1P mainly play opposing roles in cells. Because of this, there exist a balance between 
levels of ceramide and S1P, in what has been referred to as sphingolipid rheostat 2. An 
imbalance in this rheostat determines the cell’s fate whether it is towards proliferation or 
cell death.  
Ceramide, the central molecule in the sphingolipid metabolism is generated in 
cells by three main pathways (Figure 1); the de novo synthesis pathway, the salvage 
pathway and sphingomyelin breakdown. In de novo synthesis, Serine Pamitoyl 
Transferases (SPT/SPTLC), catalyze the condensation of serine and pamitoyl-CoA to 
generate 3-ketosphinganine, which is rapidly reduced to dihydrosphingosine by 3-
ketosphinganine reductase. Through the activity of (dihydro) ceramide synthases 
(dihydro-CerSs/CerSs) the dihydrosphingosine is acylated to dihydroceramide. 
Dihydroceramide is then desaturated by Dihydroceramide desaturase (DES) to yield 




There are six known mammalian Ceramide Synthases (CerS1-6) (Table 1). 
Different CerSs generate ceramides of varying fatty acid lengths 4. Ceramide Synthase 
1(CerS1) is known to generate C18-ceramide. Studies show that C18-ceramide functions 
as a pro-death ceramide, accumulation of this ceramide species has been linked to 
induction of apoptosis 5, autophagy 2 and mitophagy 6-8. Ceramide Synthase 2 (CerS2) is 
known to catalyze the generation of longer-chain ceramide species C22-24 ceramide 9. 
Conversely, C24-ceramide is known to inhibit rather than induce cell death in cancer 
cells 10. Ceramide Synthase 3 (CerS3) is mainly localized in testis and tissues and is the 




Ceramide	 is	 generated	 by	 multiple	 pathways	 including	 de	 novo	 synthesis,	




>C26, these very long ceramides are critical for forming the water barrier in the skin 11 . 
Ceramide synthase 4 (CerS4), like CerS1, generates C18- ceramide. In addition to C18-
ceramide, it also produces C20-ceramide. Lack of CerS4 and its products has been 
implicated in cell migration and hair growth cycle 12, 13. Ceramide synthase 5 (CerS5) and 
ceramide synthase 6 (CerS6) both generate mainly C12, C14, and C16 ceramides 14. 
CerS6 and its product C16 ceramide have been implicated in induction of ER stress 15. 
The role of C16 ceramide varies depending on the cell type and conditions as it has been 
shown to have both pro-apoptotic 16 and pro-proliferative 17. Several groups have shown 
the significance of the chain length of the fatty acid in ceramide molecules in conferring 
their functions. Because of this, it is important for investigators to not generalize the 




Ceramide product Biological Role 
Ceramide synthase 1 
(CerS1) 
C18 ceramide • Induces cancer cell death 5 
• Decreases tumor growth 18 
• CerS1 mutant mice have neurological disorders 19 
Ceramide synthase 2 
(CerS2) 
C22-24 ceramide • C24 ceramide can protect from cell death 20 
• CerS2 knockout mice exhibit liver damage 21 




• CerS3 knockout leads to trans-epidermal water loss 
leading to death after birth 22 
Ceramide synthase 4 
(CerS4) 
C18 and C20 
ceramide 
• CerS4 knockout mice exhibit severe alopecia with 
alterations in sebaceous glands and sebum contents 12 
Ceramide synthase 5 
(CerS5) 
C12, C14, C16 
ceramide 
• Implicated in induction of autophagy mediated 
hypertrophy of cardiac myocytes 23 
Ceramide synthase 6 
(CerS6) 
 
C12, C14, C16 
ceramide 
• Increases cancer cell proliferation 17 
• Increased expression associates with positives lymph 
nodes status 15 
• Induces chemotherapy mediated apoptosis 10 






Table adapted from Mohammed Dany and Besim Ogretmen, Ceramide induced 
mitophagy and tumor suppression 25. 
The salvage (recycling) pathway involves the conversion of sphingosine, a 
breakdown product of ceramide, back to ceramide. Ceramide is broken down to 
sphingosine and a fatty acid through the activity of ceramidases 26. Sphingosine, a 
bioactive molecule can then be phosphorylated by sphingosine kinases, sphingosine 
kinase 1 (SK1) and sphingosine kinase 2 (SK2) to generate sphingosine 1 phosphate 
(S1P), which is known to be involved in many cellular pathways 27. Excess sphingosine 
can also be converted back to ceramide by ceramide synthases, hence the name salvage 
pathway 3. It should be noted therefore that inhibition of ceramide synthases not only 
inhibits the de novo synthesis pathway, but also the salvage pathway, unlike the 
inhibition of serine palmitoyl-CoA transferases, which target only the de novo ceramide 
synthesis. S1P can also be metabolized into ethanolamine-1 phosphate and hexadecanal 
through the activity of S1P lyase. 
Ceramide can also be generated through the breakdown of complex sphingolipids 
like glycosphingolipids 28, 29. Glycosphingolipids have been shown to serve crucial roles 
in cells including regulating cell growth, differentiation and neoplastic transformation 30. 
Additionally, sphingomyelins can be broken down to generate ceramide and 
phosphatidylcholine, through the activity of sphingomyelinases (SMases).  
Ceramide can also be modified to generate different sphingolipid molecules. 
Ceramide kinase (CERK) 31 or SM synthase (SMS) 32 generate ceramide-1-phosphate 
(C1P) and sphingomyelin, respectively (Figure 2). Ceramide is also utilized by 
glucosylceramide synthase (GCS) as a precursor for the generation of GlcCer 33. GlcCer 
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is then transported from early Golgi to distal Golgi compartments by four-phosphate 
adaptor protein (FAPP2) for the synthesis of glycosphingolipids, determining the lipid 
composition of the plasma membrane 34. Non-vesicular C1P trafficking between 
membranes is regulated by a transporter protein GLTPD1 (renamed as C1P transporter 
protein, CPTP), which then controls prostaglandin signaling and inflammation 35.  
Ceramide is hydrolyzed by ceramidases (CDases) to yield sphingosine, which is 
phosphorylated by sphingosine kinase 1 or 2 (SK1 or SK2), to generate sphingosine-1-
phosphate (S1P). S1P engages with S1P receptors (SIP 1-5/S1PR1-5) in an 
autocrine/paracrine manner for oncogenic signaling 36. S1P is usually rapidly (within 10-
20 min in cells/tissues) metabolized by S1P phosphatases 37 or S1P lyase 38, yielding 




Figure adapted from Besim Ogretmen and Yusuf Hannun,  Biologically active 





Ceramide can be formed de novo (pink) or from hydrolysis of sphingomyelin, SM 
(blue) or cerebrosides (green). Ceramide can be phosphorylated by ceramide kinase to 
yield ceramide 1 phosphate (C1P) or can serve as a substrate for the synthesis of SM or 
glycolipids. Ceramide can be metabolized (orange) by ceramidases (CDases) to yield 
sphingosine, which in turn is phosphorylated by sphingosine kinase (SK) to generate 
sphingosine-1-phosphate, S1P. S1P can be cleared by the action of specific 
phosphatases that regenerate sphingosine or by the action of a lyase that cleaves S1P 
into ethanolamine-1-phosphate and a C16-fatty aldehyde. C1PP, ceramide 1-phosphate 
phosphatase; CRS, cerebrosidase; CK, ceramide kinase; CS, ceramide synthase; DAG, 
diacylglycerol; DES, dihydroceramide desaturase; GCS, glucosylceramide synthase; 
PC, phosphatidylcholine; S1PP, S1P phosphatase; SMS, sphingomyelin synthase; 
SMase, sphingomyelinase; SPT, serine palmitoyl transferase.	




2. Ceramide in programmed cell death and tumor suppression 
	
 Induction of cell programmed cell death in cancer cells has been applied as one 
means to induce tumor suppression. Some of the programmed cell death implicated in 
tumor suppression include apoptosis, autophagy and programmed necrosis (necroptosis) 
39. Addition of exogenous ceramide analogs and/or induction of endogenous ceramide 
accumulation have been implicated in the induction of caspase dependent as well as 
caspase independent programmed cell death. It has been shown that cells generate 
ceramide and sphingosine during cytotoxic stress.  
 
a) Apoptosis 
Apoptosis is a form of programmed cell death involving the activation of cysteine 
proteases known as caspases 40. Cellular phenotypes known for cells undergoing 
apoptosis include DNA fragmentation, cell shrinkage, chromatin condensation and 
membrane blebbing. Induction of apoptosis is well studied in cancer as a regulated form 
of clearing cancerous cells without triggering the inflammatory response.  
Ceramide has been implicated in apoptosis induction in cancer cells. Ceramide 
was initially reported to induce apoptosis in leukemia cells 41. Since this initial report 
ceramide-mediated apoptosis has been intensively investigated and reported in many 
other different cancer types 1. C2 and C16-ceramides have been shown to form large 
channels (ceramide channels) in mitochondrial membranes. Formation of these types of 
channels promoted mitochondrial outer membrane permeabilization (MOMP) and 
apoptosis 42, 43. Interestingly, very long ceramides and dihydroceramides have been 
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shown to greatly destabilize these channels 44, 45, showing a possible mechanism of how 
these channels and ceramide-mediated apoptosis are regulated.  C16-ceramide, generated 
by CerS6 has also been shown to be increased in TRAIL (tumor necrosis factor-related 
apoptosis-inducing ligand) induced apoptosis 46. This study found that SW620 colon 
cancer cells, which were resistant to TRAIL, had low levels of CerS6 and elevation of 
this enzyme increased their sensitivity to TRAIL, leading to apoptosis.  
Resisting cell death is one of the hallmarks of cancer 47 and cancer cells have 
evolved ways to evade apoptosis. One known way is by modulating the sphingolipid 
rheostat, leading to decreased ceramide and increased S1P generation, which has been 
associated with proliferation (reviewed in 48). Manipulation of the sphingolipid 
metabolism pathway to increase ceramide generation and promote apoptosis has been one 






Autophagy, from the Greek word meaning, “self-eating” is a cellular process 
whereby the cell digests some of its organelles, during starvation conditions to provide 
nutrients to itself 49. In some instances, autophagy has been shown to promote caspase 
independent cell death, also known as lethal autophagy.  
As in the case with apoptosis, ceramide has also been shown to play critical 
signaling roles in autophagy. Accumulation of ceramide induces both types of autophagy 
25, 50, 51. In lethal autophagy, ceramide leads to autophagy by modulating the expression of 
autophagic proteins like Beclin-1 52. In another study, ceramide was shown to induce 
autophagy in amino acids deprivation through mTOR suppression 2. Additionally, 
dihydroceramide has also been shown to induce autophagy. In glioma cells, 
Tetrahydrocannabinol (THC, the active component of marijuana) triggered 
dihydroceramide accumulation in the endoplasmic reticulum (ER), promoting 
autophagosomal and lysosomal membrane permeabilization, leading to cathepsin release 
and apoptosis 53. Expectedly, sphingomyelin accumulation, by silencing SMPD1, has 
been correlated with aggregation of elongated and unclosed autophagic membranes with 








Ceramide has been implicated in multiple cell death pathways in cancer. Ceramide can 
induce apoptosis through caspase activation, necroptosis through PP2A and RIPK1 
activation and mitophagy through targeting autophagolysosomes to the targeted 
organelles or by macro-autophagy by promoting maturation of autophagosomes. 
Figure	3 : Ceramide involvement in cell death	
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Ceramide has also been implicated in a more organelle specific type of autophagy 
known as mitophagy. Mitophagy is the digestion of cell’s mitochondria to provide 
nutrients to the cell during starvation or in some instances to induce cell death 55. 
Accumulation of C18-ceramide, exogenously added or induced through CerS1 activation, 
was shown to specifically accumulate in the mitochondria and propagate mitophagy 
through tethering of LC3B to the mitochondria in head and neck (HN) cancer cells 8 
(Figure 3). This phenomenon has also been observed in AML (acute myeloid leukemia) 
cells. Interestingly, the addition of exogenous C18 pyridinium ceramide (LCL461), 
which is specifically targeted to the mitochondria because of the positively charged 
pyridinium ring, induced mitophagy and this overcame FLT-3 mediated chemoresistance 
7.  It was also shown that ceramide-dependent lethal mitophagy was regulated by the 
activation of DRP1 and mitochondrial fission, involving PKA inhibition and decreased 
phosphorylation of DRP1 at S637 in FLT3+ AML cells 7. In addition, HPV/E7 protein 
has been shown to confer its sensitivity to chemotherapy through increased C18-ceramide 
levels which promotes mitophagy in HN cancer cells 6.  
 
c) Necroptosis 
  Necroptosis is a form of programmed cell death that involves the activity of 
receptor interacting proteins (RIPKs) (Figure 4). Necroptosis has been shown to play a 
role in both physiological and pathological settings 56. In cells, RIPK1 is typically poly 
ubiquitinitated via K63-linked ubiquitin chains by CIAPs (cytoplasmic inhibitors of 
apoptosis) and signals for NFkB activation 57. In canonical necroptosis, activation of 
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death receptors leads to activation of RIPK1 through de-ubiquitination by CYLD 58, De-
ubiquitination of RIPK1 increases its affinity for RIPK3 and other adaptor proteins to 
signal for necroptosis as opposed to pro-survival NFkB signaling 57-60 . Activated RIPK1 
recruits and phosphorylates RIPK3. Phosphorylated RIPK3 (active) then phosphorylates 
MLKL (mixed-lineage Kinase domain-like) a pseudo kinase. Phosphorylated MLKL 
oligomerizes and the oligomers translocate to the plasma membrane where they form 






Figure was taken from Meng et.al, Necroptosis in tumorigenesis, activation of anti-tumor 
immunity, and cancer therapy 64. 
 
 
Figure	4 : Necroptosis signaling	
Activation of RIPK1 from extracellular and intracellular stimuli leads to activation of 
RIPK3 followed by recruitment and activation of MLKL and plasma membrane 
disintegration. 
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Ceramide has been shown to be involved in necroptosis in lung and ovarian 
cancer. In lung cancer, studies indicate that C18-ceramide binds I2PP2A/SET (Figure 3), 
an endogenous inhibitor of tumor suppressor PP2A, leading to the activation of PP2A, 
which leads to RIPK1 activation, through unknown mechanism 65. However, the exact 
mechanisms of this activation remain unclear. In ovarian cancer, exogenous ceramide, 
through ceramide nanoliposomes was shown to activate MLKL 66. U937 lymphoma cells 
treated with a combination of TNFa and ZVAD underwent necroptosis and exhibited a 
significant increase in the levels of C16-ceramide, indicating a role of this ceramide 
species in necroptotic signaling 67. 
Although in this dissertation study, I focused on the role of ceramide in 
necroptosis, it is important to note that, in addition to programmed cell death, ceramide 
has also been implicated in other cellular mechanisms that lead to tumor suppression. 
These include ER stress and cell cycle arrest, discussed below. 
 
d) Ceramide and ER Stress 
Induction of ceramide-associated ER stress was reported as an upstream regulator 
of autophagy 68. Melanoma differentiation associated gene-7 (mda-7) regulated IL-24 
induced ER stress, leading to ceramide-mediated lethal autophagy in glioblastoma cells 
69. Methotrexate-induced folate stress in lung cancer cells increased the formation of ER 





e) Ceramide and cell cycle arrest 
Ceramide’s inhibition of cancer progression has also been shown to occur through 
cell cycle arrest. In MOLT4 leukemia cells, ceramide and its metabolite sphingosine led 
to the dephosphorylation Retinoblastoma protein (Rb), which led to cell cycle rest in 
Go/G1 and growth suppression 71. Exogenously added C6 ceramide was shown to arrest 
rhabdomyosarcoma (RMS) cells in G2 phase and eventual apoptosis of these cells 72. 
Additionally, exogenously added C2 ceramide also induced cell cycle arrest in Bel7402 
hepatocarcinoma cells 73. 
 
3. Ceramide generation in chemotherapy/radiation-mediated tumor suppression 
	
CerS-generated ceramide was linked to daunorubicin-induced apoptosis in various 
cancer cells 74. Vorinostat and sorafenib combination was efficacious in the inhibition of 
gastrointestinal tumor and pancreatic tumor-derived xenograft growth in mice. The 
mechanism involved activation of CD95 through the generation of Ca+2 and CerS6-
dependent ceramide, leading to PP2A and ROS signaling 75. In a phase II clinical trial in 
patients with recurrent HN cancers, elevation of serum C18-ceramide was significantly 
associated with improved response to gemcitabine plus doxorubicin combination therapy, 
which induced CerS1/C18-ceramide 76.  
In intestinal stem cells, Ataxia telangiectasia (ATM) kinase regulates target 
switching to escalating doses of radiation via activation of ceramide synthesis, without 
affecting microvascular response 77. Interestingly, neutralizing ceramide signaling by 
anti-ceramide antibody prevented gastrointestinal damage in response to radiation, 
relieving gastrointestinal syndrome mortality 78. Measurement of plasma ceramide levels 
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during the treatment of 35 patients with hypo-fractionated stereotactic body radiation 
therapy showed that elevated total ceramide was associated with positive response 79. 
Moreover, ABC294640, a pharmacological inhibitor of SK2, which was shown to also 
inhibit DES, resulting in the accumulation of dihydro-ceramides 80, has been successfully 
tested in a phase I clinical trial for the treatment of patients with advanced solid tumors 
81. Thus, these data suggest that increased (dihydro) ceramide generation in cancer cells  
in response to chemotherapy or radiation play important roles in tumor suppression. 
 
4. Ceramide metabolism in tumor immunology and immunotherapy 
	
  In addition to its roles in chemo/radiotherapy, ceramide signaling is implicated in 
the regulation of tumor immunology and immunotherapy. C16-Ceramide inhibited the 
growth of myeloid derived suppressor cells (MDSCs) by activating lysosomal cathepsin 
B/D and inducing autophagy in these cells 82. Induction of autophagy and ER stress in 
MDSCs enhanced cytotoxic T cell lymphocyte function for tumor suppression 82. In 
Gaucher’s disease patients, who are susceptible to myeloma, clonal immunoglobulin was 
reactive against lyso-glucosylceramide, which is highly elevated in these patients due to 
deficiency in glucocerebrosidase 83. These data suggested that lyso-glucosylceramide 
might be involved in the origin of myeloma and/or Gaucher’s disease-associated 
gammopathy 83. Interestingly, in Gaucher’s disease complement signaling via C5a/C5aR1 
induced GlcCer accumulation and tissue inflammation 84. Recently, Sofi et.al 
demonstrated that CerS6/C16-ceramide enhanced T-cell response to alloantigens during 
allogeneic hematopoietic cell transplantation (allo-HCT), an effective immunotherapy for  
	 20	
various hematologic malignancies 85. The data revealed that genetic loss of CerS6 
prevented graft versus host disease (GVHD), a major toxicity limiting the anti-leukemic  
efficacy of allo-HCT 85. Thus, these data suggest that ceramide metabolism/signaling 
plays key roles in the regulation of anti-cancer immunotherapy. 
 
5. Targeting sphingolipid metabolism and signaling for cancer therapy. 
	
  Given the importance of sphingolipids in promoting cancer progression or 
inhibition, sphingolipids have become great targets for cancer therapy. Highly soluble 
pyridinium-ceramides, selectively accumulating in cancer cells’ mitochondria, induced 
lethal mitophagy 7, 8 and tumor suppression in HN, AML and prostate cancers 86, 87. 
Inhibition of survivin by nanoliposomal ceramide (NLC) resulted in complete remission 
of the natural killer type of aggressive large granular lymphocytic leukemia 88. NLC is 
now tested in a phase I clinical trial for the treatment of patients with advanced solid 
tumors (NCT02834611).   
 
The table below shows some of the anticancer that target the sphingolipid 













Modified table adapted from Besim Ogretmen, Sphingolipid metabolism in cancer 




The US Food and Drug Administration (FDA) approved FTY720 
(Fingolimod/Gilenya, Novartis, Inc), for the treatment of relapsing MS 105, 106. 
Mechanistically, FTY720 is phosphorylated in cells by one of the two sphingosine 
kinases, sphingosine kinase 2 (SK2) 105, 106 to generate P-FTY720. P-FTY720 is 
Table	2:	List	of	anticancer	drugs	targeting	sphingolipid	metabolism	
Name  Target or activity Stage of Development 
Ceramide inducers and analogues 
C8 CPC (C8-
cyclopropenylceramide) 
DES Preclinical 89 
CHC (3-chloro 8b-
hydroxycarapin-3,8-hemiacetal) 
CERT: ceramide trafficking, 
sphingomyelin synthesis 
Preclinical 90 
NVP-231 CERK Preclinical 91 
LCL 521 and LCL 204  Preclinical 92-94 
Pyridinium ceramide (LCL-124 
and LCL-461) 
 Preclinical 86, 87 
Nanoliposomal ceramide Surviving, MLKL Preclinical 66, 88 
Targets of S1P metabolism and signaling 
FTY720 S1PR1;I2PP2A FDA-approved for multiple 
sclerosis 65, 95-97 
JTE013 S1PR2 Preclinical 98 
AB1 S1PR2 Preclinical 99 
SK1-I SK1 Preclinical 100 
PF543 SK1 Preclinical 101 
VPC03090 S1PR1;S1PR3 Preclinical 102 
Sphingomab (sonepcizumab) S1P Phase II 103 
ABC294640 SK2; DES Phase 1b and II 81, 104 
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trafficked to outside the cell by SNSP2 107, the same transporter that traffics S1P. On the 
plasma membrane P-FTY720 binds S1P receptors (S1PRs) where it acts as a functional 
antagonist (Figure 5). There are five S1PRs (S1PR1-5), and P-FTY720 binds all of them 
except S1PR2 108. Binding of P-FTY720 to the S1PRs leads to their internalization and 
degradation. Degradation of S1PRs after P-FTY720 binding disrupts the S1P gradient, 
usually maintained to allow T cells egress from lymph nodes to the bloodstream, hence 
conferring its immune suppressive property.  
 
	
To induce immune suppression, important for multiple sclerosis, FTY720 is 
phosphorylated by SK2 to generate P-FTY720 which binds S1PRs and leads to their 
degradation. In cancer, the prodrug, FTY720 (without phosphorylation) induces different 
types of cell death depending on cell type and other conditions. 
 
 
Figure	5 : FTY720 signaling in multiple sclerosis and cancer 
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FTY720 (prodrug) also exhibited tumor suppression via S1PR-dependent 109 and 
receptor-independent 65 mechanisms (Figure 5). Receptor-independent mechanism 
involves inducing necroptosis via inhibition of onco-protein SET and activation of tumor 
suppressor PP2A signaling in various cancer types, including lung, oral and colon cancers 
65, 110, 111. Another tumor-suppressor mechanism results in inhibition of CML stem cell 
proliferation/expansion, reversing CML drug resistance 97. FTY720 has also been shown 
to induce apoptosis in multiple myeloma through down regulation of anti-apoptotic 
protein, MCL-1 112 and activation of caspases 8, 9 and 3 113. Intriguingly, FTY720 
induced apoptosis even in cells that were known to be resistant to common 
chemotherapeutic agents 113. In glioblastoma, FTY720 was shown to induce tumor 
suppression by activating more than one type of cell death 114, demonstrating the diversity 
in the different mechanisms of cell death induced by FTY720 in different cell types. 
These data suggest that sphingolipid metabolism and signaling present a valuable target 
for cancer therapy. Although cancer cell death activity of FTY720 requires micro molar 
(10-20 µM) concentrations to be effective in cell culture studies, tumor suppression in 
human lung cancer xenografts grown in mice was achieved using physiologically 
relevant concentration (3 mg/kg/day) via induction of necroptosis in vivo 65.  
FTY720 has also been shown to either increase cancer cells’ sensitivity to 
chemotherapeutic agents, or radiation, when used in combination with other 
chemotherapeutic agents in multiple cell lines. In multiple myeloma, when used together 
with bortezomib 112, dexamethasone, or anti-Fas antibody 113 the cells exhibited increased 
apoptosis. When used in combination with Cisplatin, FTY720 was shown to induce 
autophagy-related apoptosis in non-small cell lung carcinoma, sensitizing cells initially 
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resistant to cisplatin 115. In triple negative breast cancer model, FTY720 was used in 
combination with an EGFR inhibitor, leading to tumor suppression 116 and also sensitized 
breast cancer cells to radiation 117.  
In addition, FTY720 has been used as a lead compound in developing inhibitors 
for specific ceramide synthases: ST1060 inhibited CerS2, ST1072 inhibited CerS4 and 
CerS6, while ST1058/1074 inhibited CerS2 and CerS4 118. These chemicals provide 
valuable preclinical tools to distinctly regulate various CerS enzymes and their specific 
ceramide products in different cancer models. In fact, inhibition of CerS6 by ST1072 
reduced T cell activation in response to allogeneic stimulation in mouse and human T 
cells, preventing GVHD toxicity during allo-HCT for anti-leukemia therapy 85. Inhibition 
of GCS by PDMP (D-thereo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol) 
sensitized CML cells expressing mutant Bcr-Abl (T315I) to tyrosine kinase inhibitors by 
inducing glycogen synthase kinase-3 (GSK-3)-dependent apoptosis 119. Overall these 
studies show the potential of FTY720 and its analogues as chemotherapeutic agents, as 
stand-alone or in combination with other agents. 
 
7. FTY720 modulation of sphingolipid metabolism 
	
FTY720 has been shown to modulate different sphingolipid molecules by 
interacting with the enzymes of the sphingolipid pathways to induce cell death. Multiple 
studies have shown, in colitis and cancer models, that FTY720 reduced the expression of 
SK1 109, 120. Another study on the contrary, found that FTY720 also inhibited S1P lyase 
121, the enzyme known to cleave S1P. This suggested FTY720 was cleaved and 
dephosphorylated by other enzymes. This led to further studies that identified several 
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enzymes that metabolize FTY720. CYP4F hydroxylates and oxidizes FTY720 for 
elimination 122, while Lipid phosphate phosphatase, LPP3 123 and LPP1a 124  
dephosphorylate P-FTY720. Moreover, FTY720 has been shown to inhibit ceramide 
synthases and lead to dihydrosphingosine 1-phosphate accumulation in human lung 
endothelial cells 125. Accumulation of dihydrosphingosine-1 phosphate shows this 
inhibition is of the de-novo synthesis pathway of ceramide generation. Interestingly, 
another study by Lahiri, S. et. al., found that FTY720 could also modulate Ceramide 
syntheses activity via a mixture of uncompetitive and noncompetitive inhibition 126. As 
before-mentioned, ceramide accumulation in cells has been implicated in caspase 
independent cell death 7, 25 including necroptosis 127 and mitophagy 128. However, 
whether FTY720 has any implication for ceramide generation and/or signaling during 
necroptosis in lung cancer is a question that still remains unanswered.  
 
8. Ceramide signaling in stem cells  
	
 Sphingolipids have also been implicated in normal and cancer stem cells biological 
activities. In Glioblastoma, S1P signaling was found to be crucial for maintenance of 
stemness in glioblastoma cells 129. In non-pathological context, ceramide and S1P have 
been shown to play key roles in embryogenesis by regulating stem cell differentiation 130, 
131. In one study, ceramide generated from neutral sphingomyelinase and de novo 
synthesis propagated primary ciliogenesis and promoted differentiation in embryonic 
stem cells and neuroprogenitors 132. This study showed that inhibition of ceramide 
generation significantly reduced ciliogenesis, which was restored with addition of 
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exogenous ceramide 132. These studies further illustrate the key roles played by 
sphingolipids in both physiological and pathological conditions.  
 
9. Ceramide signaling in Drosophila melanogaster 
	
 To study ceramide signaling in-vivo, Drosophila melanogaster (D. melanogaster) 
ovaries are a great model as they contain different types of stem cells 133. In D. 
melanogaster, ovary development (oogenesis) begins with the formation of cyst of 
interconnected germ cells, produced by germline stem cells, enveloped by somatic 
follicle cells 134. Oogenesis in insect cells requires a complex mechanism for 
differentiation of germ line and somatic cells 135. The Drosophila ovary contains three 
types of stem cell populations, germline stem cells (GSC), somatic stem cells (SCC) and 
escort stem cells (ESC), which are contained in a well-defined anatomical structure called 
germarium 136-138. Thus, insect ovaries present an ideal model to study the roles of various 
mechanisms in the regulation of stem cell development and signaling.  As opposed to 
mammals, D. melanogaster has only one isoform of ceramide synthase, known as 
schlank 139. Predictably, knocking out schlank in D. melanogaster is lethal 139, 





This figure was adapted from Abels et. al., A Genetic Mosaic Screen Reveals 






Figure	6 : Drosophila melanogaster oogenesis	
A. Drosophila oogenesis is fueled by the activity of germline stem cells. The Drosophila 
ovary is composed of 14–16 ovarioles, each harboring a germarium and older follicles that 
progress through 14 distinct stages of development. B. shows the germarium. The germarium 
contains germline stem cells (GSCs; pink) that are juxtaposed to cap cells, the major cellular 
component of the somatic niche (purple), and a subset of escort cells (blue). GSCs divide to 
form daughter cells (cystoblasts), which divide four additional times to form 16-cell germline 
cysts (peach) composed of nurse cells and an oocyte. Follicle stem cells (FSC; dark green) 
divide to form pre-follicle cells, which surround the 16-cell germline cyst, and pinch away 
from the germarium, forming a follicle. Pre-follicle cells give rise to a variety of specialized 
follicle cells (fc; green) that reside in an epithelial monolayer around each cyst. 
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Given the importance of ceramide in programmed cell death tumor suppression and 
with the knowledge that FTY720 induces RIPK3-MLKL independent necroptosis in lung 
cancer cells, in this study, I sought to investigate if FTY720- induced necroptosis was 
ceramide dependent. It is important to note that FTY720-induced necroptosis in lung 
cancer cells differs from the canonical necroptosis, in that it is RIPK3 and MLKL 
dependent. This leaves a gap in knowledge of how the plasma membrane integrity is 
compromised during this type of necroptosis. FTY720 has been shown to modulate 
ceramide signaling and this could also be occurring during the induction of necroptosis. 
Putting this knowledge together, I investigated the potential of ceramide modulation by 
FTY720 to affect the plasma membrane integrity, independent of MLKL. Additionally, I 
investigate the role of ceramide-enriched macrodomains in a non-pathological context, 












CHAPTER TWO:  MATERIALS AND METHODS 
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Cell lines and Reagents 
A549, and H1341 human lung cancer cells were grown in DMEM containing 10% FBS 
(Cellgro) and 1% penicillin/streptomycin (Cellgro), WT MEFs and NHFL were grown in 
DMEM with 10% FBS and 1% Pen/Strep. Cells were treated with the following reagents: 
FTY720, P-FTY720, NBD-FTY720, Latrunculin A (Cayman Chemical Company), OSU-
2S (was a gift from Dr. Chen, Ohio State University), Myriocin (Sigma), LPA (Santa 
Cruz Biotechnology), Brefeldin A (Sigma), AZ10606120, ARRY 520, K858, Ciliobrevin 
(Tocris), Blebbistatin (Selleckchem), Necrosulfonamide, NSA (EMD Millipore), 
Sphingosine, (Avanti Polar Lipids), Fumonisin B1, FB1 (Enzo) Biotinylated C6-ceramide 
(Echelon Biosciences). Full length recombinant RIPK1 was purchased from Origene. The 
antibodies used were Ceramide MB154 (Enzo), cholesterol (US Biological) RIP-1 (Cell 
Signaling), non-muscle Myosin IIA, b-Actin (Sigma), GM130, Calnexin, Eaa1, CD63, 
Caveolin-1, CerS5, CerS6, Acid Ceramidase (Santa Cruz Biotechnology). Nanogold 
Gold- antibody Conjugates, (mouse and Rabbit) were from Nanoprobes. a1B1 
(University of Iowa, Developmental Studies Hybridoma Bank). Rhodamine phalloidin 
and YO-PRO-1 were purchased from Life sciences (Thermo Fisher Scientific). 
DUOLINK Proximity Ligation Kit and streptavidin-coated 96 well plates were purchased 
from Sigma. 
 
Plasmid constructs and shRNAs  
The shRNA lentiviral plasmids were purchased from sigma-Aldrich. The TRC numbers 
and sequences are as follows: shMYH9 (gene ID: 4627), TRCN0000285480, sequence: 
CCGGGCCAAGCTCAAGAACAAGCATCTCGAGATGCTTGTTCTTGAGCTTGGC
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TTTTTG, shRIPK1, (gene ID 8737), TRCN0000200006, sequence:  
CCGGCGGAACAGATTCTGGTGTCTTCTCGAGAAGACACCAGAATCTGTTCCG
TTTTTTG, shCerS1 (gene id: 10715), TRCN0000168211, sequence: 
CCGGCTACTTCTTCTTCAATGCGCTCTCGAGAGCGCATTGAAGAAGAAGTAGT
TTTTTG, shCers2 (gene id: 29956), TRCN000276376, sequence:  
CCGGCCTGCCTTCTTTGGCTATTACCTCGAGGTAATAGCCAAAGAAGGCAGG
TTTTTG, shCerS4 (gene id: 204219) TRCN0000016986, sequence:  
CCGGGTTACATGATTCCTCTGACTACTCGAGTAGTCAGAGGAATCATGTAACT
TTTT, shCerS5 (gene id: 91012) TRCN0000022221, sequence: 
CCGGGTGGGCTTTATCACTATTATACTCGAGTATAATAGTGATAAAGCCCACT
TTTT, shCerS6 (gene id: 253782) TRCN0000344342, sequence: 
CCGGGAACTGCTTCTGGTCTTACTTCTCGAGAAGTAAGACCAGAAGCAGTTCT
TTTTG, shSPT1 (gene ID:10558) TRCN0000303825 sequence: 
CCGGGCTATTCCTGCTTACTCTAAACTCGAGTTTAGAGTAAGCAGGAATAGCT
TTTTG, shSPT2 (gene ID: 9517) TRCN0000286903, sequence: 
CCGGGCTCATACCAAAGAAATACTTCTCGAGAAGTATTTCTTTGGTATGAGCT
TTTTG, shSPT3 (gene ID: 55304) TRCN0000136363, sequence: 
CCGGCAAACATCTCATGGGCAACTACTCGAGTAGTTGCCCATGAGATGTTTGT
TTTTTG, shSMPD3/nSMase2 (gene ID: 55512) TRCN0000048943 
sequence:CCGGCCCAACAAGTGTAACGACGATCTCGAGATCGTCGTTACACTTG
TTGGGTTTTTG, SMPD4/nSMase 3 (gene ID: 55627) TRCN0000245620, sequence: 
CCGGCCTGAAAGCTGACTCTATAAACTCGAGTTTATAGAGTCAGCTTTCAGGT
TTTTG,  shSK2 (gene ID: 56848) TRCN0000036973, sequence:  
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CCGGCTACTTCTGCATCTACACCTACTCGAGTAGGTGTAGATGCAGAAGTAGT
TTTTG, RIPK3 (gene ID: 11035) TRCN0000002261, sequence: 
CCGGCTACAGCTTCGGGATCCTAATCTCGAGATTAGGATCCCGAAGCTGTAG
TTTTT, pMD2.G (Addgene plasmid #12259) and pCMV-psPAX2 (Addgene plasmid # 
12260) were gifts from Dr. Didier Trono. Non-targeting shRNA (shSCR) was used as 
control.  
 
Stable shRNA knockdown studies  
CerS1, CerS2, CerS4, CerS5, CerS6, SPT1, 2, 3, nSMase 1, 2, 3, SK2, RIPK1, RIPK3, 
MYH9 and non-targeting shRNA containing plasmids (purchased form the MUSC 
shRNA shared Technology Resource) were co-transfected in HEK293 packaging cells 
with together with pCMV-psPAX2 and pMD2.G plasmids to generate lentiviral particles. 
The lentiviral particles were collected after 48Hrs. These were added to H1341/A549 
cells, together with 10µg/mL polybrene. After 48 hours, the lentiviral particles were 
removed and cells were selected for approximately 14 days with 2µg/mL puromycin.  
 
Site Directed Mutagenesis  
RIPK1 D147A, N148A, N169A, N186A, L112A, C256A, R258A, L293A, E295A 
mutants were generated using Q5 site-directed mutagenesis kit (New England Biolabs) 
per manufacturer’s instructions. Primers were designed using NEBaseChanger (New 


















Cultured cells were incubated the respective treatment, washed two times with 1X PBS, 
fixed with pre-warmed 4% paraformaldehyde (PFA) for 15 minutes at room temperature, 
permeabilized for 10 minutes with 0.01% Triton X-100, blocked for 20 minutes with 1% 
BSA before incubation with primary antibody in blocking solution overnight at 4°C. The 
following day the cells were incubated with secondary antibody (Alexa fluor-488 anti-
mouse) and Rhodamine phalloidin. The coverslips were mounted on slides with a drop of 
Prolong anti-fade reagent (Invitrogen), and sealed with nail polish. Labeling patterns 
were observed using Olympus FV10i Laser Scanning confocal microscope. Images were 
analyzed by Flouview Fv10i software. Ceramidosomes quantification was performed 




Proximity Ligation Assay 
Proximity ligation assays were performed using Duolink in situ red kit (Olink 
Biosciences, Sigma) per manufacturer’s instructions. Antibodies were used at 1:100 
dilution, probed overnight at 4° C. Images were analyzed as described previously 141. 
 
Co-Immunoprecipitation and Western blotting 
For immunoprecipitation, cells were grown to 70% confluency, treated with FTY720 or 
vehicle, cells were rinsed with cold 1X PBS, scrapped off and lysed in Pierce IP lysis 
buffer (non-denaturing) with protease inhibitor cocktail and phosphatase inhibitor. 
Immunoprecipitation was done with RIPK1 or Myosin IIA antibody. Lysates were 
precleared with 40µl of protein A/G beads and control IgG and incubated in a rotatory 
shaker for 1 hr at 4°C. Samples were centrifuged at 2,000Xg for 5 minutes. The 
supernatant was collected and incubated with the respective antibody at 4°C for 1 hr 
before adding 40µl agarose beads and rotating overnight. The following day, samples 
were centrifuged at 2,000 g for 5 minutes; the beads were washed with cold 1X PBS four 
times, followed by the addition of 2X loading dye. The samples were boiled using a 
heating block before western blotting. For assays cells were homogenized in RIPA buffer 
(25mM Tris-HCl pH7.4, 150mM NaCl, 1% TritonX-100,1% sodium deoxycholate, 
EDTA (20µl of 0.5M stock) including protease inhibitor cocktail using a gauge (26.5G) 
syringe five times, incubated for 20 minutes on ice. The samples were centrifuged at 
12,000Xg for 15 minutes at 4ºC. The supernatant was collected and proteins were 
quantified with Bradford method. 4X loading dye was added to sample and boiled using a 
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heating block at 95ºC for 5 minutes before loading. SDS gradient gels 4%-20% were used 
to run the samples with Bio Rad Criterion apparatus, followed by semi-dry transfer onto 
PVDF membrane. Blocking was done with 5% milk in 0.1% PBST. Primary antibodies 
were used at 1:2000 dilution overnight at 4ºC. Proteins were analyzed by Western 
blotting using the following antibodies: the rabbit RIPK1 (Cell signaling), β-actin 
(Sigma, St. Louis, MO), anti-GFP (Santa Cruz), Non-muscle Myosin IIA (Sigma).  
 
Quantitative RT-PCR  
RNA was extracted from cell pellets using RNeasy kit (Qiagen) per the manufacturer’s 
instructions. cDNA was generated using equal amounts of RNA from each sample and 
iScript cDNA synthesis kit (Bio-Rad) per manufacturer’s instructions. The thermal cycler 
protocol used was as follows; Priming (5 min at 25°C) followed by Reverse transcription 
(20 min at 46°C) and RT inactivation (1 min at 95°C).  Reactions were carried out using 
SsoAdvance universal probes mix (Bio-Rad) and TaqMan primer probes (ThermoFisher 
Scientific) in a BioRad CFX96 RealTime system.  The thermal cycling protocol used was 
as follows:  Polymerase activation and DNA denaturation at 95°C for 30 sec, followed by 
40 amplification cycles (denaturation at 95°C for 10 sec and annealing/extension and 
plate read at 60°C for 30 sec).  
 
Membrane permeability/Dead cell apoptosis kit with YO-PRO-1 and PI 
Cells were cultured to 70-80% confluency, and then treated with 20µM FTY720 or 
vehicle. The cells were collected by scrapping off the dishes, rinsed with cold 1X PBS, 
resuspended in 1 mL cold PBS dyes were then added at 1µl/mL concentration. The 
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samples were kept on ice for 20-30 minutes before analysis by flow cytometry on 
LSRFortessa/X-20. For live cell imaging, cells were treated with 20µM FTY720 or 
vehicle and incubated with the dyes (1µl/mL). Pictures were taken every 30 minutes for a 
period of 3 hrs. For the RIPK1 mutants, membrane permeability was analyzed by 
propidium iodide only in GFP positive cells. 
 
Trypan blue exclusion assay  
Cells were seeded in 6-well plates and allowed to adhere for 20 hours. Treatment was 
with 20µM FTY720 in DMSO, or corresponding amount of vehicle control. Medium 
containing dead cells was pelleted with trypsinized cells, then re-suspended in 1X PBS 
then counted with a hemocytometer after addition of trypan blue dye (Sigma-Aldrich) at 
a 1:10 dilution.  
 
Lipidomics analysis 
Cells were collected by scrapping off from the dishes and washed twice with cold PBS. 
Further preparation of samples and measurement of endogenous ceramides by LC-
MS/MS followed the protocol described previously 142. Briefly, samples were 
supplemented with internal standards, and 2 ml of isopropyl alcohol:water:ethyl acetate 
(30:10:60; v:v:v) was added to the extracts. Samples were subjected to two rounds of 
vortex and sonication followed by a 10-min centrifugation at 4000 rpm. The supernatant 
or top layer was used as lipid extract and subjected to LC-MS/MS for analysis of 
ceramide species. Lipid extraction and analyses were performed by the MUSC 
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Lipidomics Shared Resources. Inorganic phosphates (Pi) were used for normalization. 
Detailed protocol for inorganic phosphates analysis can be found in the Appendix. 
 
Isolation of Ceramide-enriched membrane pores  
We followed previously published protocol for isolating Giant Plasma membrane vesicles 
143, 144. In summary, cells were grown in 100 mm dishes to 80% confluency. These cells 
were treated with Vehicle/ FTY720. The cells were rinsed twice with GPMV buffer (10 
mM HEPES, 150 mM NaCl, 2 mM CaCl2, pH 7.4) and incubated with vesiculation buffer 
(25 mM PFA/2 mM DTT in GPMV buffer, to prepare add 18µl of 4%wt/vol PFA 
solution and 2µl of 1M DTT solution to 1mL GPMV buffer) for 1hr at 37ºC incubator. 
GPMV (ceramidosomes) were collected and processed for electron microscopy.  
 
Ceramide Docking to RIPK1 
Using the software MOE from CCG 145, a complete contiguous model of the kinase 
domain from RIPK1 was created based on Xray-derived coordinates PDB:4NEU and 
5HX6 146, 147. The protein was protonated at T=310K, pH 7.3, salt at 200mM, and using 
GB/VI electrostatics.  The final structure was energy minimized using the AMBER12: 
ETH forcefield.  C16-ceramide was docked to the RIPK1 monomer using the entire 
surface as a target.  Initial placement calculated 100 poses using triangle matching with 
London dG scoring, the top 50 poses were then refined using forcefield and Affinity dG 




Molecular interaction analysis  
The heterodimer structures from pdb:3L82 and the best heterodimer output from ClusPro 
for Fbxo4:Fxr1 were interrogated for intermolecular contacts.  Protein contact thresholds 
were 4.5 for hydrophobic interactions, 4.2 for ionic bonds, 2.5 for disulfide bonds with a 
sequence separation of 4 and a network separation of 0.  Molecular images were prepared 
using MOE, as we described previously 8, 141. 
 
Molecular modeling of ceramidosomes forming membrane pores 
The theoretical model was created in several steps, as we have previously described.  
First the top C16-RIPK1 results from the in-silico probe was duplicated in order to make 
a symmetric RIPK1 homodimer containing two molecules of ceramide. Two mode 
ceramides were added per molecule of RIPK1 and placed along the active site as a stack 
in order to create homodimer of RIPK1 with six total ceramides. Finally, the CBD of 
NMIIA was attached to each molecule of RIPK1.  This was done using a prediction 
derived from a CluPro protein-protein interaction simulation. Part of the recognition 
domain of CBD from myosin molecules is defined and uses a conserved amphipathic 
helix (E1547-K1555 in the case of NMIIA). A NMIIA (also known as MYH9) CBD domain 
homology model was created using the CBD (also known as a globular tail domain 
GTD)) from MyoVa (PDB:4KP3) 148. Using the structural file for RIPK1 and the CBD of 
NMIIA, bimolecular docking was performed. Using the docking servers ClusPro server, 
the RIPK1 structure (as described above) was uploaded as the ligand and the NMIIA 
CBD structure was uploaded as the receptor. The binding residues were not selected nor 
were any residues selected to block docking and default settings were used to allow 
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maximum freedom of docking poses. The best pose and four of the top 10 poses indicated 
an interaction with the E1547-K1555 helix and indicated it is favored interaction site. Using 
protein superposition between the CluPro results and the aforementioned RIPK1 dimer, 
the CBD was attached to each molecule of RIPK1. 
 
Quantitative detection of ceramide-RIPK1 binding  
H1341 cells were transfected with GFP-tagged RIPK1 WT, RIPK1 N169A, or empty 
vector (pEGFP.N1). Cells were lysed by freeze-thawing in non-denaturing buffer: 50mM 
Tris (pH7.4), 150 mM NaCl, 1mM EDTA, 0.5% NP-40 and 1:500 protease inhibitor 
cocktail. Lysates (2 mg protein) were precleared with 40µl agarose beads. The precleared 
lysates were incubated with GFP-magnetic beads at 4ºC for 18 hrs with gentle agitation. 
The beads were then washed with 1X PBS and incubated with unlabeled ceramide or 
biotin ceramide in 200µl of binding buffer. RIPK1-biotin-ceramide complexes were 
quantified using competitive ELISA with streptavidin coated plates. The results were 
analyzed using GraphPad Prism 7 software, as we previously described 8, 141. 
 
Ultrastructural analysis using Transmission Electron Microscopy (TEM) 
A549 cells were collected by scrapping off tissue culture plates. Rinsed with 1X PBS and 
fixed in 2% glutaraldehyde in 1X PBS. After post-fixation with 2% (vol/vol) osmium 
tetroxide, specimens were embedded in Epon 812, and sections were cut orthogonally to 
the cell monolayer with a diamond knife. These sections were visualized with a 




Immunogold analysis using transmission electron microscopy 
H1341 cells were treated with FTY720/vehicle, collected by scraping the cells off the 
plate using cell lifter. The cells were washed with 1X PBS and fixed for 15 minutes with 
4% paraformaldehyde. The cells were washed again 2X with 1X PBS, and permeabilized 
with 0.01% saponin. The saponin was rinsed off 2X with 1X PBS, followed by blocking 
for 20 minutes with 1% BSA (in 1XPBS) and incubated with primary antibody (1:100) at 
4ºC for 18 hrs. After primary antibody incubation, the cells were pelleted by centrifuging 
for 5 minutes at 1,300 rpm. The pellets were then rinsed 2X with 1% BSA, before 
incubation with secondary antibody (gold-conjugated Donkey anti-mouse/rabbit) at 1:200 
dilution for 1 hr at room temperature. Finally, the cells were washed 2X with 1% BSA 
and post-fixed with 1% glutaraldehyde (in 1XPBS) for 10 minutes, then kept in ddH2O. 
The staining was enhanced by silver staining before imaging. 
 
Scanning Electron Microscopy (SEM) 
Post treatment, samples were fixed with primary fixative (2% glutaraldehyde, 2% 
paraformaldehyde in 0.1 M cacodylate buffer pH 7.35).  Secondary fixation was achieved 
with 1% osmium tetroxide in 0.1 M cacodylate buffer.  After both fixation steps, samples 
were washed three times with ddH2O then dehydrated with increasing ethanol 
concentrations (20% to 100%).  Samples were submerged in 100% ethanol and critical 
point drying was achieved with a Tousimis Autosamdri-931 (Rockville, MD).  Before 
imaging, 3-6 nm iridium was applied to samples and images were acquired with a 
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Magellan 400 field emission scanning electron microscope (FEI) (Hillsboro, OR) at the 
Notre Dame Integrated Imaging Facility.  
 
Germline knockdown of zipper  
Fly stocks were obtained from Bloomington Drosophila Stock Center and maintained at 
25°C. zipper was knocked down in the germline by driving zipper shRNA using Gal4-
nos.NGT. Adult ovaries in F1 progeny from this cross were rudimentary. 
 
Drosophila ovaries immunostaining and microscopy 
Immunostaining of ovaries was performed as described earlier 149. a-Ceramide was used 
at 1:100 150. a-1B1 was obtained from Developmental Studies Hybridoma Bank, Iowa 
and used at 1:50 dilution. Confocal images were taken using Zeiss LSM 880 NLO 
microscope and Plan-Apochromat 63x/1.40 Oil DIC objective. Images were analyzed 
using Fiji (ImageJ).  
 
Immuno-gold labeling of Drosophila ovaries 
Isolated ovaries from D. melanogaster flies were stained with gold-labeled ceramide as 
described in 151. Briefly, paraformaldehyde tissues were sliced into ultra-thin sections 
using a microtome. The sections were mounted on carbon-coated copper grids. The grids 
were then rinsed, blocked and incubated with ceramide antibody, then gold labeled 




FB1 exposure of D. melanogaster 
10-15 adult male and female OregonR flies were exposed to food containing 100 µM 
FB1. Flies not exposed to FB1 were used as control. F1 generation flies from exposed 




Data were reported as mean ± standard deviation. Statistical analysis was performed by 
ANOVA or Student’s t-test using Prism/GraphPad software version 7; p <0.05 were 













1. FTY720 induces loss of PM integrity, which can be inhibited by Blebbistatin 
	
To confirm that FTY720-mediated necroptosis was associated with plasma 
membrane alteration, a known occurrence in necroptosis, we carried out live cell 
imaging, transmission electron microscopy (TEM), and scanning electron microscopy 
(SEM) studies. We treated GFP-expressing A549, non-small cell lung cancer cells with 
FTY720 or vehicle (DMSO) and carried out live cell imaging over a period of 240 
minutes. Our data showed that FTY720 induced membrane blebbing, followed by plasma 
membrane rupture and necroptosis in a time dependent manner (Figure 7A-B). Using 
A549 cells without GFP, we were also able to detect compromised plasma membrane 
with YO-PRO1 152 and propidium iodide (PI) dyes (Figure 7C), used to detect plasma 
membrane breaks and cell death. We further detected the plasma membrane breaks 
and/or holes using transmission electron microscopy and scanning electron microscopy in 
cells treated with FTY720 (Figure 8 A-B).  
Interestingly, FTY720-mediated blebbing and plasma membrane rupture was 
largely abrogated when the cells were pretreated with blebbistatin 153, a known inhibitor 
of non-muscle myosin IIA (NMIIA)-mediated blebbing in A549 cells detected using live 
cell imaging (Figure 9A-B) and trypan (Figure 9C). Concurrently, Blebbistatin 
pretreatment inhibited the plasma membrane breaks/holes in cells, detected by SEM 
(Figure 10). Thus, these data suggest that FTY720-mediated necroptosis is linked to 
NMIIA-mediated blebbing, resulting in membrane rupture and cell death.  
 Moreover, alterations of the plasma membrane integrity and induction of 
necroptotic cell death in response to FTY720 were also evident with YOPRO-1 and PI 
dyes in H1341, a small cell lung cancer cell line, using live cell imaging (Figure 11A) 
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and flow cytometry (Figure 11 B-C). This was confirmed using trypan blue exclusion 
assay (Figure 11 D).   
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A. A549-GFP cells were treated with 20µM FTY720 and their morphological changes 
monitored over a period of 240 minutes. Frozen frames of the time lapse experiment 
show plasma membrane blebbing before rupture and disintegration of cells treated with 
FTY720, quantified in B. Data are means ± SD from three independent experiments, 
analyzed by paired student t-test (n=3, *P= 0.002**P=0.004***P=0.002). C. Effect of 
FTY720 on cells’ plasma membrane integrity. Live cell imaging in A549-GFP cells 
shows plasma breakage as evidenced by incorporation of propidium iodide dye (red) in 
A549 cells.  
Figure	7 : Loss of plasma membrane integrity in A549 cells in response to FTY720 
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Figure	8 : Electron microphotographs A549 and H1341 cells after FTY720 
treatment	
 
A. TEM micrographs show plasma membrane breaks (compromised plasma membrane, 
shown with black arrow) in FTY720 (20µM) treated A549 cells. B. SEM micrographs 
show pores (shown with black arrows) and compromised plasma membrane in H1341 






A. A549-GFP cells were pretreated with blebbistatin (12.5µM for 2hr) before FTY720 
treatment shows and time lapse images were taken to monitor changes in morphology. 
Blebbistatin treated cells showed protection from plasma membrane rupture induced by 
FTY720, quantified in B, Data are means ± SD from three independent experiments, 
analyzed by paired student t-test (n=3, *P=0.03**P<0.0008). C. Trypan blue in A549 





Figure	10 : Blebbistatin pretreatment inhibits FTY720-induced plasma membrane 
holes	
 
SEM micrographs show protection of the hole punctures in plasma membrane in cells 






Figure	11 : FTY720 treatment induces plasma membrane permeability and cell 
death in H1341 cells	
 
A. H1341 cells were imaged with YOPRO-1(green) and PI (red) dyes after exposure to 
FTY720.  B. Flow cytometry indicate increased necroptosis in cells treated with FTY720 
versus vehicle (DMSO). Flow cytometry data is quantified in C. Data represents means ± 
SD from three independent experiments, analyzed by paired student’s t-test (n=3, 
*P=0.02).  D. Trypan blue exclusion assay shows significant trypan blue inclusion with 
FTY720 treatment. Data represents means ± SD from three independent experiments, 
analyzed by paired student’s t-test (n=3, ***P<0.0001).		
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2. FTY720 induces ceramide-enriched macrodomains on the PM 
	
Because FTY720-induced necroptosis was independent of RIPK3 and MLKL 65, 
and FTY720 is known to modulate ceramide synthesis, we investigated whether FTY720-
mediated necroptosis is linked to ceramide generation, a bioactive lipid that is known to 
alter membrane integrity and induce blebbing 154. Surprisingly, there were no detectable 
changes in the overall abundance of ceramides in response to FTY720, measured by 
LC/MS/MS in A549 total cell lysates (Figure 12).  
In addition to the amounts of sphingolipids, their localization, also confers their 
role in the cell 6-8, 155. Because of this, we investigated whether FTY720 exposure resulted 
in the changes in ceramide subcellular localization. Interestingly, in A549 cells, FTY720 
led to the formation of ceramide platforms/macrodomains on the plasma membrane, as 
detected by immunofluorescence using two distinct anti-ceramide antibodies 150, 156 
(Figure 13 A-B). There was no accumulation of S1P or cholesterol on the plasma 
membrane, as detected by anti-S1P or anti-cholesterol antibodies respectively 157,158 
(Figure 13 C-D). Moreover, treatment of cells with NBD-FTY720, a fluorescently 
tagged FTY720, showed no sign of drug accumulation on plasma membrane of A549 
cells (Figure 13 E), suggesting that FTY720 itself does not accumulate in ceramide-
enriched membrane macrodomains, which appear to be around 1-2 microns in diameter.  
To confirm the presence of ceramide in the FTY720-mediated membrane 
macrodomains, we depleted ceramides in H1341 cells by overexpressing acid ceramidase 
(AC) 92, 159, an enzyme that hydrolyzes ceramide to sphingosine and fatty acid. Ectopic 
expression of AC using adenoviral particles (Ad-GFPAC), reduced total ceramide levels 
(Figure 14 A) and abrogated the formation of ceramide-enriched membrane 
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macrodomains (Figure 14 B-C). Figure 14 D Shows the expression levels of AC 
compared to Ad-GFP control. Taken together, these data suggest that FTY720 exposure 
induces the formation of membrane pores, which are enriched in endogenously generated 





Figure	12 : FTY720 does not alter ceramide generation in A549 cells 
 
A549 cells treated with FTY720 (20µM, 2hr) show no significant changes in the 
ceramide levels in A549 cells after treatment. Data represents means ± SD from three 





Figure	13 : FTY720 induces ceramide-enriched membrane macrodomains 
 
A. A549 cells were treated for 2hr, with 20µM FTY720, stained for ceramide and F-actin 
(Rhodamine phalloidin) and imaged using laser scanning confocal microscopy, evidence 
of ceramide-enriched macrodomains in the plasma membrane. Right panel at the bottom 
represents a zoom-out of the framed area. Scale bar represents 100 µm. B. A549 cells 
treated with FTY720 (20µM, 2hr) stained with a different ceramide antibody (Rabbit 
anti-ceramide) and F-actin also show the ceramide-enriched membrane macrodomains. 
C. A549 cells treated with FTY720 (20µM, 2hr) and stained for S1P using anti S1P 
antibody (1:100) and in D, cholesterol using anti-cholesterol antibody (1:100) as controls 
for ceramide antibody staining. E. A549 cells treated with NBD-labeled FTY720 (20µM, 





Figure	14 : FTY720-induced macrodomains are specifically made up of ceramide	
 
A. Effects of AC overexpression on cells’ lipidomics profile was determined by LC/MS/MS, 
there was significant decrease in total ceramide levels. Data represents means ± SD from three 
independent experiments, analyzed by paired student t-test (n=3, *P=0.047). B. Ad-GFP-AC 
was over-expressed in H1341 cells, the cells were treated with 20 µM FTY720 48 hr post-
transduction and stained for ceramide-enriched membrane pores. This is quantified in C. Data 
are means ± SD from three independent experiments, analyzed by paired student t-test (n=3 
*P=0.02. **P=0.03). D. Western blot shows AC expression compared to Ad-GFP control.	
  
	 56	
3. Ceramide-enriched macrodomains are novel structures 
	
The ceramide-enriched macrodomains were not detectable in the Golgi, ER, early 
endosomes, caveolin-enriched lipid microdomains, or exosomes in response to FTY720 
in these cells (Figure 15 A). In addition, the macrodomains were only induced by 
FTY720 and its non-phosphorylatable analogues. This was studied by exposing A549 
cells to other sphingolipids, such as myriocin (as FTY720 is a myriocin analogue), 
sphingosine, S1P and lysophosphatidic acid (LPA), all of which, did not induce the 
ceramide-enriched macrodomains. Exposure of cells to FTY720 and its non-
phosphorylatable analogue OSU-2S 160 largely mediated ceramide-enriched membrane 
pores formation (Figure 15 B). In addition, a FTY720-mimetic selected from the 
ChemBridge library in silico (compound 5) was also able to induce ceramide-enriched 
membrane pores, suggesting that ceramidosome formation is not dependent on selective 
FTY720 exposure.  
As expected, phosphorylated FTY720 (P-FTY720) did not induce ceramidosomes 
(Figure 15 B). We confirmed this by knocking down sphingosine kinase 2 (SPHK2 or 
SK2), the key enzyme that phosphorylates FTY720 to P-FTY720. Knocking down SK2 
had no effect on ceramidosomes formation compared to controls, scrambled (SCR)-
shRNA-transfected and vehicle-treated cells (Figure 16 A-B). FTY720 and P-FTY720 
levels were measured in A549 cells using mass spectrometry-based lipidomics 142 
(Figure 16 C) and data showed significant decrease in P-FTY720 with SK2 knockdown, 
further confirming that ceramidosomes were induced by FTY720 but not P-FTY720. 







A. A549 cells were treated with FTY720 and stained for ceramide and different organelle 
markers GM130 (golgi) calnexin (ER), Eea1(Early endosomal markers), caveolin-1 
(caveolin-1-enriched lipid rafts), CD63 (Exosomes). Ceramide-enriched membrane pores 
did not co-localize with any of the stained organelles. B. A549 cells were treated with 
different lipid compounds (20 µM), ceramide and F-actin (Rhodamine phalloidin) were 





Figure	16	:	SK2 knockdown does not affect FTY720-induced ceramide-enriched 
macrodomains	
 
A. H1341 cells with stable SK2 knockdown were stained for ceramide-enriched 
membrane pores.  The ceramide-enriched macrodomains are quantified in B, using 
ImageJ. Data represents means ± SD from three independent experiments, analyzed by 
paired student t-test (n=3, ns= not significant *P=0.05, **P=0.04). C. Lipidomics 
analysis of the level of FTY720 and P-FTY720 in H1341 cells with SK2 stable 
knockdown. Data represents means ± SD from three independent experiments, analyzed 
by paired student t-test (n=3, **P<0.0001) D. qRT-PCR data shows the level of SK2 
mRNA after knockdown. Data represents means ± SEM from three independent 
experiments, analyzed by paired student t-test (n=3, **P<0.0001).	
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4.  Different cell lines respond differently to FTY720 to form Ceramide-enriched 
membrane pores 
	
During our experiments, we found that H1341 cells required almost tenfold less 
FTY720 to induce ceramide-enriched pores compared to A549. In H1341 cells, induction 
of ceramidosomes was detected with 0.1-1 µM FTY720 for 60 min as opposed to 10µM 
in A549 cells (Figure 17 A-C), showing cell specificity and unique response to FTY720. 
Interestingly, while ceramide-enriched membrane pores formation in response to FTY720 
was evident in multiple cancer lines including H1650 (non-small cell lung cancer, 
NSCLC), H1341 (small cell lung cancer, SCLC) and 22A (head and neck squamous cell 
carcinoma, HNSCC) (Figure 18 A), they were not detected in non-cancerous skin 
keratinocytes, normal human lung fibroblasts (NHLF) and NIH3T3 mouse embryonic 
fibroblasts (Figure 18 B). Collectively, these data suggest that FTY720 and FTY720 
mimetics, but not P-FTY720, mediate the formation of ceramidosomes in various cancer 
cells, but not in non-cancerous keratinocytes or fibroblasts, in a dose and time-dependent 
manner preceding blebbing, lysis of the plasma membrane and necroptosis. The 
mechanisms mediating these differences between cell lines remain to be investigated. 
Given the novelty and specificity of these ceramide-enriched membrane pores formed by 












Figure	17	:	FTY720 dose titration shows different sensitivity between H1341 and 
A549 lung cancer cells 
 
A. H1341 and A549 cells were treated with increasing concentrations of FTY720 for two 
hours and stained with anti-ceramide antibody and Rhodamine phalloidin to check 
evidence of ceramide-enriched membrane pores with immunofluorescence. B. A time 
course experiment was carried out in H1341 cells. The cells were treated with 10 nM 
FTY720 for different time periods and stained with anti-ceramide antibody and 
rhodamine phalloidin to check evidence of ceramide-enriched membrane pores with 
immunofluorescence. The ceramide-enriched membrane pores are quantified in C. Data 





Figure	18	:	Cancer cells but not non-cancerous cell form ceramide-enriched 
membrane macrodomains	
 
A. Multiple cancer cell line were treated with Vehicle (DMSO) or 20 µM FTY720 for 2 
hr and stained for ceramide and F-actin. B. Non-cancerous cells (keratinocytes, normal 
human lung fibroblast (NHLF) and NIH3T3) were treated with FTY720 (20µM for 2hr) 
or vehicle and showed no evidence of ceramide-enriched membrane pores.	
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5. Ceramide in FTY720-induced ceramidosomes is mainly C16-ceramide 
	
 To investigate the source of the ceramide enrichment in membrane pores in 
response to FTY720, we generated A549 cells stably expressing shRNAs against 
enzymes that catalyze ceramide generation. We knocked down neutral sphingomyelinase, 
SMase (nSM1-3), serine pamitoyl transferases, SPT (SPT1-3), and Ceramide synthases, 
CerS1, CerS2, CerS4, CerS5, and CerS6 using lentiviral particles. We omitted CerS3 
because of its selective expression in skin and testes 161. ShRNA-dependent knockdown 
of nSMases (Figure 19 A) or SPT enzymes (Figure 19 B-D) had no effect on 
ceramidosomes formation with/without FTY720. 
Interestingly, knockdown of ceramide synthase 5 or 6, which generate C16-
ceramide, but not CerS1, CerS2, or CerS4, abrogated ceramidosomes and protected cells 
from necroptosis in response to FTY720 (Figure 20 A-B), (mRNA levels are shown in 
Figure 20 C). Reduction of C16-ceramide by silencing CerS5 and/or CerS6 was 
confirmed by lipidomics compared to Scr-shRNA-transfected controls (Figure 20 D). 
Thus, these data suggest that ceramidosomes mainly contain C16-ceramide generated by 
CerS5 and/or CerS6 in response to FTY720. The fact that the SPT enzymes did not affect 
ceramidosomes formation suggests a possible role for the salvage pathway in generating 
the C16 ceramide generation for ceramidosomes formation. 
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Figure	19	:	Sphingomyelinases and serine pamitoyl transferases are not involved in 
ceramidosomes formation 
 
A. The effects of genetic loss of SMases were studied in A549 cells with stable 
knockdown of different nSMases. Knocking down nSMases did not abrogate ceramide-
enriched membrane pores. B. H1341 cells with stable SPT knockdown were stained for 
ceramide-enriched membrane pores. Knocking down SPT did not significantly abrogate 
ceramide-enriched macrodomains. This is quantified in C. Data represents means ± SD 
from three independent experiments, analyzed by paired student t-test (n=3, *P=0.01). D. 
mRNA expression levels in the shSPT stable knockdown cells were determined by qRT-
PCR. Data represents mean ± SEM from three independent experiments, analyzed by 




Figure	20 : C16 ceramide in ceramidosomes is generated by CerS5 and CerS6 
 
A. Effects of genetic loss of ceramide synthases on ceramidosomes formation were 
measured using immunofluorescence with ceramide antibody and Rhodamine phalloidin 
(F-actin) in H1341 cells with CerS1 CerS2, CerS4, CerS5, CerS6 shRNA, compared to 
scramble (shscr) shRNA. ceramide-enriched membrane pores were manually quantified 
B. Data represent means ± SD from three independent experiments. Analyzed by student 
t-test (n=3, *P<0.05) Scale bar represents 100 µm. C. mRNA expression levels in the 
shCerS 1, 2, 4, 5, 6 stable knock-down cells were determined by qRT-PCR. Data 
represents mean ± SEM from three independent experiments, analyzed by paired student 
t-test (n=3, *P=0.04, **P=0.005, ***P=0.001, ****P<0.0001). D.  Lipidomics analysis 
was carried out in H1341 cells with stable CerS5 and 6 knock-down. Data are means ± 




6. Ceramidosomes mediate RIPK1-dependent necroptosis 
	
Because our previous studies indicated FTY720-mediated necroptosis was 
dependent on RIPK1, but not RIPK3 65, we assessed whether RIPK1 played any role in 
the formation of ceramidosomes in response to FTY720. To determine if RIPK1 is 
localized within ceramide-enriched membrane pores, we first measured the co-
localization of RIPK1 and ceramide by immunofluorescence using anti-RIPK1 and anti-
ceramide antibodies. FTY720 exposure induced the co-localization of RIPK1 and 
ceramide compared to vehicle-treated controls within plasma membrane (Figure 21 A). 
This co-localization between RIPK1 and ceramide was also detectable by immunogold 
TEM using gold labeled anti-RIPK1 (labeled with 10 nm gold particles) and anti-
ceramide (labeled with 1.4 nm gold particles) antibodies (Figure 21 B) and proximity 
ligation assay (PLA) using anti RIPK1 and anti-ceramide antibodies (Figure 21 C-D) in 
response to FTY720 compared to vehicle-treated controls. Thus, these data suggest that 
RIPK1 is co-localized with ceramide at the plasma membrane within ceramidosomes in 
response to FTY720-mediated stress.   
Then, to determine if RIPK1 was necessary for ceramidosome formation, we 
measured the effects of RIPK1 knockdown on ceramidosomes in response to FTY720. 
ShRNA-mediated knockdown of RIPK1 prevented ceramidosomes formation in response 
to FTY720 (Figure 22 A-B), (protein expression in panel C), and protected cells from 
necroptosis compared to Scr-shRNA-transfected and vehicle-treated cells (Figure 22 D).  
In contrast, knocking down RIPK3 using shRNA had no effect on ceramidosome 
formation (Figure 23 A-B) or cell death (Figure 23 C). (mRNA levels are shown in 
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Figure 23 D). Given that RIPK3 is known to activate MLKL, which induces membrane 
pores for the execution of necroptosis 61, 162, we also measured the effects of MLKL 
inhibition on ceramide-enriched membrane pores formation, using a pharmacological 
inhibitor necrosulfonamide (NSA) 162. NSA-mediated MLKL inhibition had no effect on 
FTY720-mediated ceramidosome formation (Figure 23 E-F) or necroptosis as tested by 
trypan blue assay (Figure 23 G).  
As an additional control, we also explored other known pore-forming proteins that 
could be involved in the execution of FTY720-mediated necroptosis. To achieve this, we 
investigated the effects of purinergic receptor protein (P2X7), which is known to form 
membrane pores in response to cytotoxic stress such as increased ATP accumulation 163. 
Our data showed that pharmacological inhibition of P2X7 using inhibitor AZ10606120 
164 had no effect on induction of ceramidosomes (Figure 24 A-B) or necroptosis, (Figure 
24 C) in the presence of FTY720. Thus, these data are consistent with our previous 
findings, indicating that while RIPK3 and MLKL were dispensable, RIPK1 is necessary 





Figure	21	:	RIPK1 colocalizes with ceramide in FTY720-induced ceramidosomes 
 
A. Colocalization of RIPK1 and ceramide was measured by confocal microscopy. A549 
cells were treated with 20 µM FTY720 for 2 hr and stained with anti-ceramide antibody 
and anti- RIPK1 antibody and detected by immunofluorescence. Colocalization of RIPK1 
and ceramide is evident on the plasma membrane in response to FTY720 treatment. B. 
RIPK1-ceramide colocalization was further detected by immuno-gold TEM. H1341 cells 
were treated with FTY720 or Vehicle (DMSO). The electron microphotograph shows 
increased RIPK1 (10 nm gold) association with ceramide (1.4 nm gold) in cells treated 
with FTY720. C. This was confirmed in A549 cells by proximity ligation assay (PLA). 
Cells treated with FTY720 (20 µM) had increased RIPK1-ceramide association. This is 
quantified in D. Data represent means ± SD from five independent experiments, analyzed 




Figure	22	:	Knocking down RIPK1 inhibits ceramidosomes formation 
 
  
A. To study effects of RIPK1 silencing on ceramidosomes formation, A549 cell were 
stably transfected with lentiviral shRNA against RIPK1. These cells were treated with 20 
µM FTY720 or vehicle for 2 hr and stained with anti-ceramide antibody and Rhodamine 
phalloidin (F-actin). shRIPK1 cells had significantly less ceramidosomes formed as 
quantified in B. Data represent means ± SD from three independent experiments, 
analyzed by paired student t-test (n=3 *P=0.01). C. Western blot shows the RIPK1 
expression after knockdown in with RIPK1 shRNA lentiviral particles in A549 cells. 
RIPK1 was knocked down over 70%. D. LDH assay was used to study effect of RIPK1 
knockdown on FTY720-induced necroptosis. shRIPK1-A549 cells were less sensitive to 
FTY720 treatment compared to shscr cells. Data represent means ± SD from three 





Figure	23	:	RIPK3 and MLKL are dispensable in FTY720 induced ceramidosomes 
formation and necroptosis 
 
A. H1341 cells with stable RIPK3 knockdown were investigated for presence of 
ceramidosomes with/without FTY720 treatment (10µM 1hr). These were quantified as 
shown in B, Data are means ± SD from three independent experiments, analyzed by 
paired student t-test (n=3, *P=0.002). C. LDH Assay in shRIPK3 cells treated with 
FTY720 (20µM, 3hr or vehicle control). Data represents means ± SD from three 
independent experiments, analyzed by paired student t-test (n=3, *P=0.02, **P=0.005). 
D. mRNA expression of RIPK3 in the RIPK3 stable knockdown cells was determined by 
qRT-PCR. Data represents means ± SEM from three independent experiments, analyzed 
by paired student t-test (n=3, *P=0.046). E. H1341 cells were pretreated with NSA 
(MLKL inhibitor, 2.5µM for 2hr). The ceramide-enriched pores are quantified in F. Data 
represents means ± SD from three independent experiments, analyzed by paired student t-
test (n=3, *P=0.04). G. Trypan blue assay was carried out in the NSA pretreated H1341 
cells. Data represents means ± SD from three independent experiments, analyzed by 




Figure	24	:	P2X7 is not involved in FTY720 induced ceramidosomes or necroptosis 
 
A. H1341 cells were pretreated with AZ10606120 (P2X7 inhibitor, 5µM, for 1hr) before 
treatment with FTY720. The cells were then stained for the ceramidosomes. This is 
quantified in B. Data represents means ± SD from three independent experiments, 
analyzed by paired student t-test (n=3, *P=0.04). C. Trypan blue assay was carried out in 
the AZ10606120 pretreated cells. Data represents means ± SD from three independent 
experiments, analyzed by paired student t-test (n=3, *P=0.01).	
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7. RIPK1 directly binds ceramide to form ceramidosomes 
	
Ceramide-protein interaction is important for various crucial biological roles. For 
instance, ceramide binding to LC3BII targets autophagolysosomes to the mitochondria to 
induce lethal mitophagy 7, 8. Additionally, ceramide has been shown to bind CERT 
(ceramide transport protein) for trafficking to the golgi for synthesis of sphingomyelin 
165. To investigate if the association between ceramide and RIPK1 was due to their 
binding, we first measured ceramides by lipidomics after immunoprecipitation of RIPK1 
using anti-RIPK1 antibody, and lipid extractions on agarose beads used for pulling down 
possible RIPK1-ceramide complexes, as we described previously 8, 141 (Figure 25 A-B). 
These data revealed that there was an increase only in C16-ceramide in FTY720 treated 
cell extracts bound to RIPK1 compared to controls (vehicle-treated). Of note, FTY720 
did not affect RIPK1 expression levels (Figure 25 C). In reciprocal studies, binding of 
ceramide with RIPK1 was measured in-vitro using biotinylated C6-ceramide and 
recombinant human RIPK1, which were isolated by avidin-conjugated agarose beads. 
The amount of RIPK1 bound to biotin-ceramide was measured by ELISA using anti-
RIPK1 antibody. It was found that C6-ceramide bound to RIPK1 with a Kd of 1.9 nM 
(Figure 25 D), and the stoichiometry of RIPK1-ceramide binding was found as 1:2.4, 
calculated as we described previously 141. These findings further confirmed ceramide-
RIPK1 binding and indicate that at least in-vitro, RIPK1- ceramide binding is 
independent of the fatty acid chain length of ceramide. In addition, formation of dimers 
of RIPK1 upon FTY720 exposure was detected using non-denaturing western blot 
analysis (Figure. 25 E). These biochemical data were then used for in silico modeling of 
RIPK1-ceramide complex, containing RIPK1 dimer associated with four molecules of 
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C16-ceramide (Figure. 25 F). Molecular docking and simulations were done using the 
already existing X-ray crystal structure of RIPK1 166 (PDB: 4NEU and 5HX6). The top 
ranked model of the RIPK1-ceramide complex identified potential residues of RIPK1 that 
were important for ceramide binding, including D147, N148 and N169 residues.  
To confirm and validate the model for RIPK1-ceramide binding, we performed 
site directed mutagenesis to generate D147A, N148A and N169A conversions and 
measured their effects on co-localization with ceramide at the plasma membrane and 
necroptosis. The WT-RIPK1-GFP was co-localized with ceramide at the plasma 
membrane, whereas the association between ceramide and D147A-RIPK1-GFP or 
N169A-RIPK1 at the plasma membrane was reduced compared to WT-RIPK1 in 
response to FTY720 (Figure 26 A-B). Interestingly, N186A mutants, which was 
identified as a weak ceramide interacting residue, co-localized largely with ceramide in 
response to FTY720 (Figure 26 A-B). Live cell imaging of these mutants with PI dye 
after FTY720 treatment further showed the protective effect of the N169A mutant 
(Figure 27 A-B). The loss of ceramide binding of the N169A-RIPK1 was confirmed 
using biotin-C6-ceramide and partially purified N169A-RIPK1-GFP, as described above, 
which showed no binding (Figure 28 A-B). Thus, these data suggest that RIPK1-
ceramide binding plays a key role for the generation of ceramidosomes and induction of 
necroptosis after FTY720-mediated cellular stress.  
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Figure	25	:	RIPK1 binds Ceramide in response to FTY720 
 
A. Lipidomics analysis of agarose beads after RIPK1 pull down show significant binding 
of endogenous C16-ceramide to RIPK1. Data are means ± SD from three independent 
experiments, analyzed by paired student t-test (n=3, p =0.04) in response to FTY720. B. 
Western blot showing RIPK1 after pull down with anti-RIPK1 antibody and agarose 
beads in DMSO (vehicle) versus treated (FTY720) cells. C. Western blot analysis of 
H1341 cells treated with FTY720 shows no change RIPK1 relative protein abundance 
compared to vehicle treated cells. D. In-vitro ceramide binding assay with purified 
recombinant human RIPK1 show binding to biotinylated C6-ceramide with a Kd of 
~1.908 nM. E. Western blot with anti-RIPK1 antibody shows the formation of RIPK1 
dimers in non-reducing conditions in cells treated with FTY720 compared to vehicle-
treated cells. F. Molecular model of RIPK1 and ceramide showed RIPK1 dimers with 4 




Figure	26	:	RIPK1-ceramide binding is crucial for ceramidosomes formation and 
necroptosis	
 
A. Confocal images showing ceramide-enriched membrane pores formation with the 
RIPK1 mutants over-expressed in shRIPK1 cells. B. quantification of ceramidosomes in 
A. Data represents means ± SD from three independent experiments, analyzed by paired 







A. To determine effect of the RIPK1 mutants on cell death, live cell imaging experiment 
was carried out on shRIPK1 cells with EV, WT RIPK1 or N169A RIPK1 over-
expression. Cells with mutant RIPK1 showed a delay in PI dye inclusion, quantified in B. 
Data represents means ± SD from three independent experiments, analyzed by paired 






Figure	28	:	In-vitro RIPK1 mutants-ceramide binding assay	
 
 A. In-vitro binding assay of partially purified empty vector (EV), WT or N169A RIPK1 
using biotinylated C6 ceramide. Data represents means from three independent 
experiments. B. Western blot analysis shows the expression of WT and N169A RIPK1 




8. The ceramide-RIPK1 complex is trafficked to PM through vesicular trafficking 
	
 Transport of “cargo”, including lipids and lipid complexes intracellularly from 
their site of synthesis to target sites can occur in vesicular and non-vesicular fashion 167. 
Vesicular trafficking is known to be dependent on temperature, with low temperatures 
inhibiting vesicular trafficking 168. This factor can be used to distinguish between 
vesicular and non-vesicular trafficking.  
To determine whether ceramide-RIPK1 complexes are translocated to the plasma 
membrane via vesicular or non-vesicular trafficking, we treated A549 cells with FTY720 
at 37°C or at 4°C, and measured ceramide-RIPK1-enriched membrane pores. The data 
demonstrated that while ceramidosomes were formed in cells incubated at 37oC in 
response to FTY720, incubation of cells at 4oC largely prevented the formation of 
ceramidosomes at the plasma membrane. Interestingly, when cells that were incubated 
initially at 4oC were later transferred to 37oC, formation of ceramidosomes was restored 
(Figure 29 A-B), indicating the involvement of temperature sensitive trafficking, which 
is usually indicative of vesicular transport. This was confirmed by pretreating A549 cells 
with a known vesicular trafficking inhibitor, Brefeldin A (10 µg/mL) 169 for 24 hr before 
FTY720 exposure, which prevented ceramide-RIPK1 complex transport to the plasma 
membrane (Figure 29 C-D).  
We found non-muscle myosin IIA (NMIIA) was critical for the ceramidosomes 
trafficking because blebbistatin pretreatment attenuated the formation of ceramidosomes 
(Figure 29 E). However, pharmacologic inhibitors of kinesin spindle protein (ARRY520) 
170, kinesin (K858) 171 and Dynein (ciliobrevin) 172, had no effect on the formation of 
ceramide-RIPK1-enriched pores after FTY720-mediated stress (Figure 29 E). 
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Interestingly, the vesicular trafficking of the ceramide-RIPK1 complex was also 
dependent on an intact actin cytoskeleton, because inhibiting actin polymerization using 
Latruculin A (Lat A)  173 attenuated ceramidosome formation (Figure 29 F-G). Thus, 
these data suggest that NMIIA is key for the transport of ceramide-RIPK1 complex to the 
plasma membrane, and that the ceramide-RIPK1-NMIIA complex integrates 
ceramidosomes to form a membrane macrodomain and subsequent membrane pores 




Figure	29	:	Ceramidosomes are trafficked to the plasma membrane via vesicular 
trafficking 
 
A. Shows cells treated with Vehicle/ FTY720 and incubated at 4º C or 37º C for two 
hours or 4º C followed by 37º C.   This is quantified in panel B, Data are means ± SD 
from three independent experiments, analyzed by paired student t-test (n=3, ns=not 
significant *P =0.007, **P=0.005). C. A549 cells were pretreated with Brefeldin A 
(10µg/µl for 24hr) before FTY720 treatment. The cells were then stained for ceramide 
and F-actin as shown. This is quantified in panel D. Data are means ± SD from three 
independent experiments, analyzed by paired student t-test (n=3, *P =0.04, **P=0.03). E. 
Pharmacological inhibitors against Kinesin or dynein or NMIIA were used to pretreat 
A549 cells before treatment with FTY720 and immunofluorescence staining for 
ceramide-enriched pores. F. A549 cells were pretreated with latrunculin A and treated 
with FTY720 for 1 hr. Ceramide- enriched pores are quantified in G. Data represent 





9. NMIIA traffics RIPK1-ceramide complex to the plasma membrane  
	
Non-muscle myosin IIA, NMIIA, coded by the MYH9 gene is known to bind and 
traffic Golgi glycosyltransferase to the ER 174. Not only has NMIIA been implicated in 
intracellular vesicle trafficking 175, 176 but also, it has been shown to be important in tissue 
folding in D. melanogaster 177, suggesting a conserved role of this protein in both 
mammalian and lower organism level. Interestingly, MYH9 knock out is embryonic 
lethal in mice 178 and D. melanogaster 179, 180 . 
Based on the observation that blebbistatin, an inhibitor of NMIIA, also protected 
ceramide-enriched pores, we then hypothesized that NMIIA, recently identified as a 
tumor suppressor protein 181, 182, might be key for the trafficking of the ceramide-RIPK1 
complex to the plasma membrane to form ceramidosomes in response to FTY720. To test 
this hypothesis, we first measured the co-localization of NMIIA with ceramide and 
RIPK1 using immunofluorescence. FTY720 exposure induced the co-localization of 
NMIIA with ceramide and RIPK1 (Figure 30 A-B) compared to vehicle-treated controls. 
This was confirmed with tri-color colocalization of ceramide-RIPK1 and NMIIA (Figure 
30 C). The co-localization of NMIIA and RIPK1 within ceramidosomes at the plasma 
membrane in response to FTY720 was also consistent in TEM studies performed using 
gold labeled anti-NMIIA (labeled with 1.4 nm gold particles) and anti-RIPK1 (labeled 
with 10 nm gold particles) (Figure 30 D). 
 Interestingly, PLA analysis showed that while NMIIA associated highly with 
RIPK1 (Figure 31 A-B), there was almost no detectable interaction between NMIIA and 
ceramide (Figure 31 C-D). Thus, these data suggest that FTY720-mediated 
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ceramidosomes are transported to the plasma membrane by NMIIA via RIPK1-NMIIA 
association.  
Next, we determined whether NMIIA knockdown inhibited the formation of 
ceramidosomes in response to FTY720. NMIIA knockdown reduced the formation of 
ceramidosomes (80%) in response to FTY720 compared to shscr-transfected and vehicle-
treated controls (Figure 32 A-B). Down-regulation of NMIIA using shRNA also 
protected A549 cells from FTY720-mediated necroptosis compared to controls (Figure 
32 C). The expression levels of NMIIA after knockdown are shown in Figure 32 D.  
Using the tricolor Zstack confocal image, we generated a three-dimensional (3D) 
image of the ceramide-RIPK1-NMIIA complex at the plasma membrane using the using 




Figure	30	:	NMIIA colocalizes with ceramide and RIPK1 on the plasma membrane 
in response to FTY720 
 
A. Colocalization of NMIIA with ceramide in ceramide-enriched membrane pores was 
detected by immunofluorescence using anti-ceramide and anti-NMIIA antibodies (Insert 
on bottom right shows a zoom-out of the framed area). B Colocalization of RIPK1 and 
NMIIA in ceramide-enriched membrane pores was detected by immunofluorescence 
using anti-ceramide and anti-RIPK1 antibodies. C. Tricolor immuno-fluorescence of 
A549 cells with NMIIA, RIPK1, and ceramide antibodies shows the colocalization of the 
three at the plasma membrane in response to FTY720. D. Immuno-gold TEM show 





Figure	31	:	NMIIA interacts with RIPK1 in the RIPK1-ceramide-NMIIA complex 
A. PLA assay in A549 cells detects RIPK1 and NMIIA increased association in response 
to FTY720. PLA assay is quantified in B. Data represent means ± SD from three 
independent experiments, analyzed by paired student t-test (n=5 **P=0.004). C. PLA 
assay did not show interaction between ceramide-NMIIA interaction in response to 
FTY720. The detected PLA signal is quantified in D. Data represent means ± SD from 







A. A549 cells with stable NMIIA knockdown (shMYH9) were stained for ceramide-
enriched membrane pores using anti-ceramide and anti-RIPK1 antibodies. This is 
quantified in B. Data represent means ± SD from three independent experiments, 
analyzed by paired student t-test (n=3 *P=0.01, **P=0.003). C. LDH assay in stable 
shMYH9 cells treated with increasing doses of FTY720 show significant protection from 
FTY720 induced cell death. Data represent means ± SD from three independent 
experiments, analyzed by paired student t-test (n=3 *P=0.004, **P=0.01, ***P£0.0008). 





Figure	33	:	3D model of ceramidosome	
 
ImarisCell model (derived from a Zstack confocal image) shows the spatial interaction of 
components of ceramidosomes 
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10. NMIIA interacts with RIPK1 for the trafficking of the RIPK1-ceramide complex 
to the PM 
	
Because our studies suggest that trafficking of ceramide-RIPK1 complex to the 
plasma membrane was facilitated by NMIIA via its interaction with RIPK1, we then 
generated a model of the NMIIA-RIPK1 interaction, containing the RIPK1-ceramide 
complex using molecular modeling and simulations (Figure 34 A-B). This model (the 
top ranked model among various others) suggested a few possible residues of RIPK1 that 
might be involved in NMIIA interaction, including L112, C256, R258, L293, and E295 
(Figure. 34 B). We then confirmed this model by measuring the effects of WT-RIPK1-
GFP compared to various mutants of RIPK1 with L112A, C256A, R258A, L293A, or 
E295A conversions with the GFP tag on NMIIA interaction using immunofluorescence 
(Figure 35 A-B). Western blotting (Figure 35 C) shows the expression of the mutants 
after overexpression. The data showed that alterations of RIPK1-NMIIA interaction due 
to R258, L293A or E295A mutations on RIPK1 limited the formation of ceramidosomes 
in response to FTY720.  We picked L293A mutant for live cell imaging using YOPRO-1 
and PI and the mutation also protected cells from FTY720-mediated necroptosis 
compared to the cells expressing WT-RIPK1-GFP (Figure 36 A-B).  
To visualize the ceramide-RIPK1-NMIIA complex (ceramidosome) that forms 
large pores on the plasma membrane in response to FTY720, we isolated ceramidosomes 
from the plasma membrane by using the method for the isolation of giant plasma 
membrane vesicles (GPMV) 183. This method induces the vesiculation of the plasma 
membrane (“pinching off” of plasma membrane), including FTY720-induced 
ceramidosomes, which we can further study using different applications. Figure 37 A 
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shows an image of how the GPMV appear, when induced in A549-GFP cells. We treated 
H1341 cells with 10µM FTY720/vehicle and isolated the GPMV from both conditions. 
After isolation, the GPMVs were fixed and labeled using gold-labeled anti-ceramide, 
anti-RIPK1 or anti-NMIIA antibodies for visualization by TEM (Figure 37 B). The TEM 
images of these GPMVs demonstrate that while ceramide surrounds the inner channel, 
RIPK1 and NMIIA appear to have a general distribution within these vesicles consistent 
with the molecular modeling (Figure 34 A) and the three-dimensional image (Figure 
33). Overall, these data suggest that RIPK1-NMIIA interaction, involving 
R258/L293/E295 residues of RIPK1, plays a key role for the transport of ceramide-
RIPK1 complex to the plasma membrane for the formation of ceramidosomes and large 





Figure	34	:	Ceramidosome model showing key residues for interaction 
 
 A. Predicted model of ceramidosomes, showing ceramide, RIPK1, and NMIIA, (brown, 
green and blue respectively). The right panel (B) highlights the residues predicted to be 




Figure	35 : R258, L293 and E295 residues in RIPK1 are important for RIPK1-
NMIIA binding 
 
A. RIPK1 mutants were overexpressed in shRIPK1 cells, the cells were then stained for 
ceramidosomes. These are quantified in B. Data represent means ± SD from three 
independent experiments, analyzed by paired student t-test (n=3 *P=0.05, **P=0.005). C. 




Figure	36	:	L293A mutant protects cells from FTY720-induced cell death 
 
A. To determine effect of the RIPK1 mutants on cell death, RIPK1 mutant L293A, was 
overexpressed in shRIPK1 H1341 cells. The cells were then treated with 20µM FTY720 
and monitored over time for inclusion of propidium iodide dye with confocal live cell 
imaging. This is quantified in B. Data represents means ± SD from three independent 






Figure	37	:	Isolated ceramidosomes show ceramide, RIPK1 and NMIIA staining 
 
A. Image shows induced plasma membrane “pinching off” (GPMV) in A549-GFP cells. 
Ceramidosomes were isolated through this method. B. Isolated ceramidosomes were 














CHAPTER FOUR: DISCUSSION AND FUTURE DIRECTIONS  
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DISCUSSION  
In this study, our data demonstrate that the ceramide-RIPK1-NMIIA complex 
forms large membrane pores at the plasma membrane, which are referred to here as 
ceramidosomes. The formation of ceramidosomes in response to FTY720-mediated stress 
resulted in plasma membrane blebbing, leading to compromised membrane integrity and 
necroptosis in cancer cells. FTY720/ceramidosome-mediated necroptosis was RIPK1-
dependent, however, unlike canonical necroptosis, RIPK3 and MLKL were dispensable 
in this process.  We suggest that in place of MLKL, ceramidosomes are serving as the 
“executioner” in FTY720-mediated necroptosis, a term used to describe MLKL in 





 PP2A activation by FTY720/OSU-2S leads to the dimerization of RIPK1 and binding to 
C16 ceramide. This complex is then trafficked to the plasma membrane by NMIIA, 
where it forms pores on the plasma membrane and result in cell death. In non-
pathological setting, the ceramidosome complex could be serving more of regulatory 




It has been known that ceramide induced necroptosis in response to TNF-alpha-
mediated stress in L929 cells, which is protected by hydrolysis of ceramide by acid 
ceramidase 187. Studies by Lang et. al., also suggested that ceramide-mediated 
necroptosis played a key role in hyperosmotic-induced cell death in erythrocytes (suicidal 
death of erythrocytes, eryptosis), which was associated with membrane blebbing and 
necrosis 188. However, the mechanisms by which ceramide induces membrane blebbing 
and necroptosis have been unknown. A recent study showed that ceramide 
nanoliposomes induced MLKL-dependent necroptosis in ovarian cancer cells 189. Our 
data suggest that FTY720-mediated necroptosis is dependent on the formation of novel 
ceramide-enriched membrane pores (ceramidosomes), which are made up of ceramide-
RIPK1/NMIIA complex. Ceramidosome-mediated necroptosis appears to be distinct 
from canonical necroptosis, as RIPK3 and MLKL were dispensable for this process in 
response to FTY720-induced stress.       
Although ceramide was modeled to form lipid channels in vitro, and these 
ceramide channels were reported to exist at the mitochondrial membrane, which are 
disassembled by anti-apoptotic Bcl-2 family proteins 190, 191, whether ceramide channels 
in mitochondria play any roles in the regulation of cell death remain unknown. To this 
end, our studies demonstrate that FTY720-mediated ceramidosomes are formed 
intracellularly with the involvement of ceramide-RIPK1 association and are then 
trafficked to the plasma membrane through actin filaments by NMIIA. It has been shown 
that NMIIA is involved in the trafficking of protein cargo to various biological 
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membranes with distinct functions such as controlling exocytosis or positioning of 
organelles in cells 192, 193. Our data are also consistent with the tumor suppression 
function of NMIIA 194, as its genetic deletion resulted in squamous cell carcinoma 
development in mice through inactivation of p53 signaling, similar to the prevention of 
ceramidosome-mediated necroptosis by shRNA-mediated NMIIA knockdown in 
response to FTY720 in lung cancer cells. However, whether ceramidosomes were formed 
in other cell types without any external stress stimuli were unknown. 
To address this, we used D. melanogaster as a model organism, specifically 
ovaries as they contain multiple types of cells at various stages of development. The data 
suggested that ceramidosomes formed in germline stem cells, and that inhibition of 
ceramidosome formation using siRNA-mediated knockdown of zipper stunted ovary 
development potentially by inhibition of germline stem cell signaling without affecting 
their survival. Our data suggested that ceramidosomes can also form without any external 
stress stimuli, at least in the early stages of oogenesis, selectively in the germline stem 
cells in D. melanogaster. A limitation for this study however, is that there is no true 
orthologue of RIPK1 in D. melanogaster. RIPK1, closest “relative” in D. melanogaster is 
imd  195, which functions in inflammation signaling similarly to mammalian RIPK1, 
however, imd only has a death domain, which we have previously found 65 and have 
confirmed in the experiments described in this thesis, dispensable in FTY720-induced 
necroptosis. There could be other protein (s) in D. melanogaster that could serve a similar 
role to RIPK1 in ceramidosomes formation, but this remains to be investigated.  
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Inhibition of ceramide synthesis or knockdown of NMIIA (zipper) limited 
ceramidosome formation and ovary development, suggesting important roles for 
ceramidosomes in germline stem cells signaling during oogenesis. 
Although we have shown the presence of ceramidosomes in D. melanogaster 
ovaries, the mechanisms by which ceramidosomes regulate oogenesis are unknown and 
need to be determined. It is known that there are nanotubes in the D. melanogaster testes, 
which mediate niche stem cell signaling 196. It remains unknown whether ceramidosomes 
play similar roles in ovaries. It is possible that ceramidosomes might play a role in the 
regulation of germ line stem cell niche organization by enhancing EGFR signaling, as 
demonstrated previously by the involvement of nuclear pores and lamina 197, 198.    
 Thus, this thesis presents a novel lipid-multiprotein complex, involving ceramide-
RIPK1 and NMIIA complex, which is trafficked to the membrane to form pores, 
ceramidosomes, inducing membrane rupture and necroptosis in response to FTY720 in 




In our previous study, we found that FTY720 induced a non-canonical type of 
necroptosis that was independent of RIPK3 and MLKL. This begged the question of the 
downstream targets of RIPK1 in FTY720-induced necroptosis. With knowledge from 
literature indicating ceramide’s ability to form membrane pores and FTY720 ability to 
modulate ceramide signaling in cells we pursued this possibility in necroptosis. In this 
study, we have focused on the effects of FTY720 on ceramide generation and localization 
during necroptosis. Our studies have elucidated that in small cell (SCLC) and non-small 
cell lung cancer (NSCLC) cell lines, FTY720 does not significantly affect ceramide 
generation but does induce the formation of ceramidosomes, as discussed earlier. 
Although the findings of this study are novel and answer important questions about 
FTY720-induced necroptosis in lung cancer, there are still some unanswered questions 
that could be investigated in future research.  
We also showed, in our initial studies, that PP2A activation mediated cell death 
was mitigated by RIPK1 knockdown 65, this indicated that RIPK1 acted downstream of 
PP2A activation. Although this dissertation study explores what occurs downstream of 
RIPK1, the mechanisms of exactly how PP2A activates RIPK1 remain elusive. Our 
preliminary proximity ligation assay (PLA) studies show that there is a significant 
increase in the association between PP2A and RIPK1 in response to FTY720, however, 
whether this association is direct binding, and whether PP2A dephosphorylation of 
RIPK1 mediates its non-canonical necroptotic activity remains unknown.  
In this study, we have also demonstrated the novel role of NMIIA in trafficking 
ceramidosomes to the plasma membrane and how critical this role is in mediating cell 
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death. However, there remain myriad unanswered questions about NMIIA activation 
during FTY720-induced necroptosis. In our other unpublished data, we have also found 
out that NMIIA is a target of PP2A. This, we observe by proximity ligation studies which 
show increased PP2A and NMIIA association, as well as SILAC mass spectrometry 
studies. These findings bring about more questions about exactly how PP2A modulates 
NMIIA and how this affects NMIIA role in ceramidosomes trafficking and necroptosis.  
Additionally, this brings about the main question, of how PP2A activates both 
NMIIA and RIPK1 to induce necroptosis. Different possibilities could be investigated 
here; 1) Does PP2A dephosphorylate RIPK1? Is RIPK1 a direct target of PP2A? 2)Is 
PP2A indirectly activating RIPK1 via NMIIA? And if so, how is this occurring and 
which residues on NMIIA are dephosphorylated by PP2A. Answers to these intriguing 
questions will allow for better understanding of this mechanism and this could be 
manipulated to affect necroptosis in cancer cells versus non-cancerous cells.  
 Moreover, we have shown the varying responses of different cell lines to the same 
concentration of FTY720. Further studies could be carried out to find out the mechanism 
behind the different sensitivities among the cell lines. In our preliminary studies to 
investigate this, we examined the proteins that could bind FTY720 to either enhance or 
lessen its potency in the different cell lines, hence leading to the different responses to the 
same dose of FTY720. To study this, we treated A549 and H1341 cells with biotin-
tagged FTY720, lysed the cells pulled down the FTY720-bound proteins with 
streptavidin-coated agarose beads and run the samples on a gradient polyacrylamide gel. 
The gel was then stained with coomassie blue dye. We observed one band that was more 
	 99	
prominent in H1341 cells treated with Biotin FTY720 (Figure 39 A) compared to A549 
cells. This band was excised and analyzed by mass spectrometry.  
Interestingly, we found that in H1341 cells, compared to A549 cells, Biotin 
tagged FTY720 bound to caldesmon, a protein known to inhibit myosin-actin interaction 
in cells (Figure 39 B). FTY720 binding caldesmon could be enhancing NMIIA 
movement along actin filaments (by inhibiting the inhibitor), to promote more 
ceramidosomes on the plasma membrane and more cell death, hence making these cells 
more sensitive to FTY720 compared to A549 cells. This experiment could be confirmed 
and further investigated to better understand why this phenomenon is occurring in one 
cell line and not the other. Answers to these questions will have clinical relevance as they 
could potentially predict which type of cancer would respond more ceramidosome-










A. Coomassie blue staining of H1341 and A549 cells (treated with Biotin-
FTY720/Biotin) after IP with avidin-coated beads.  B. Expression of caldesmon, one of 
the proteins identified from mass spectrometry analysis of the band indicated by the black 
arrow in A, in H1341 and A549 after IP with avidin-coated beads. C. Expression of 
caldesmon in H1341 and A549 cells without FTY720 treatment 
 
In our studies, we have seen that ceramidosomes were only evident in cancer cell 
lines and not in non-cancer cell lines that we looked at. This lack of ceramidosomes 
formation in these cell lines also correlated with their response to FTY720. Cells that did 
not form ceramidosomes also required a lot more FTY720, almost twice as much to 
induce cell death. We still do not why non-cancerous cells did not form ceramidosomes 
in response to FTY720. This intriguing phenomenon in cells could be further investigated 
to understand the implications of this phenomenon in future cancer treatment. Could 
making normal cells more resistant to ceramidosomes formation reduce the side-effects 
typically seen in patients undergoing chemotherapy?  
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Our study showed us that ceramidosomes formed large membrane pores and 
appeared to be highly organized and well structured. Because of this and ceramide’s 
implication in stem cells differentiation and development in non-pathological conditions 
130, 131, we decided to investigate whether ceramidosomes were also formed in 
physiological condition without FTY720 exposure or any exogenous stress stimuli. To 
determine this, we elected to use D. melanogaster ovaries due to the presence of various 
stages of developmental process and stem cell types 149, 199, 200. We isolated ovary tissues 
from D. melanogaster and performed immunofluorescence using anti-ceramide and a 
germline stem cell marker, 1B1 201. Interestingly, ceramide-enriched macrodomains were 
detected colocalized with the germline stem cell marker (Figure 40 A), which also marks 
structures in the germline stem cells known as spectrosomes/fusomes 202, known to be 
key in synchronizing germline stem cells differentiation by sharing of intracellular 
contents.  
To further examine the role of ceramide membrane pores/macrodomains in the 
ovary development, we analyzed the effects of the inhibition of ceramide synthesis using 
fumonisin B1 (FB1) on the formation of ceramide-enriched macrodomains and ovary 
development. the data showed significant decrease in ceramide and 1B1 co-localization 
without affecting the survival of GSC (Figure 40 B-C), indicating a possible key role of 
ceramide in GSC signaling.   
To determine if ceramidosome play any functional roles in the ovary 
development, we obtained zipper (NMIIA homologue) 203 RNAi flies and drove RNAi 
using Nos RNAi driver. We then determined the effects of zipper knockdown on the 
formation of ceramide pores/macrodomains and ovary development. Remarkably, 
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siRNA-mediated knockdown of zipper inhibited the formation of ceramide-enriched 
macrodomains in ovaries, and resulted in a defective ovary development in insects, 
leading to a sterile phenotype (Figure 41 A-B). Overall, these data suggest that 
ceramidosome, at least containing ceramide and NMIIA homologue zipper, are possibly 
formed de novo without any external drug treatment or stress stimuli selectively in GSC 
found in the early developmental stages of ovaries. We suggest that ceramidosomes could 





A. Isolated ovarioles from D. melanogaster were stained for ceramide and stem cell 
marker (1B1) using the respective antibodies. The rightmost panel shows a zoomed-out 
picture of the framed area. B. Isolated ovaries from D. melanogaster exposed to FB1 
(100 µM)/Vehicle were stained for ceramide and 1B1. There was decreased co-
localization between ceramide and 1B1 in the flies exposed to FB1 the rightmost panels 
show zoomed-out pictures of the framed areas. Quantification of 1B1 and ceramide 
colocalization is shown in C.	
  
Figure	40	:	Ceramide colocalizes with germline stem cell marker in D. melanogaster 




A. To investigate the effect of genetic loss of zipper (NMIIA), ovarioles isolated from 
zipper RNAi flies were stained for ceramide and stem cell marker (1B1). A. shows zipper 
RNAi flies had stunted ovary development compared to Nos.Luciferase RNAi (control). 
B. shows 1B1 and ceramide staining in the germarium in Nos.Luciferase ovarioles (top 





Given that ceramidosomes (identified by ceramide antibody) were colocalized in 
with spectrosomes/fusomes in germlines stem cells and knocking down a key component 
of ceramidosomes led to defective ovary development, our data suggest that 
ceramidosomes could be involved in the trafficking of non-polar molecules like sterols 
between cells, especially germline stem cells during the early stages of oogenesis. 
However, further studies to understand if this is what is going on, need to be carried out.  
 As before-mentioned, FTY720 is currently being used to treat multipole sclerosis. 
Compared to this role, the dose required to induce cancer cell death is quite high 
compared to the dose typically required to induce immune suppression in MS. 
Predictably, the side effects for this would be deleterious to cancer patients. This 
necessitates the need for analogues of FTY720 that are more potent at lower does than 
FTY720 and possibly have less side-effects. Additionally, non-phosphorylatable 
analogues of FTY720 would be more clinically relevant for cancer treatment as they will 




Inorganic Phosphates (Pi) Analysis 
Day 1 
**make Ashing buffer 9:1:40 (10N H2SO4: 70% HClO4: H2O) (make a lot to keep at 
bench for future use) 
**Make 10mM NaH2PO4 if you don’t have this already (make a lot to keep at bench for 
future use) 
Protocol 
Add 1 mL chloroform and 2 mL methanol, vortex 
Add 800µl ddH2O, vortex 
Add 1 mL chloroform, vortex 
Add 1 mL ddH2O vortex 
Spin 3000 rpm 5 minutes 
** in the mean-time take fresh glass tubes (duplicates for each sample) and label them 
Using glass pipet, insert into bottom clear phase and take 1 mL, divide into two tubes (0.5 
mL each tube) 
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Dry under nitrogen. (turn top knob; silver (just until it’s on), then front knob to 
approximately 100 KPa. Insert pipets in tubes dry completely 
** in the meantime, make standards with NaH2PO4  
 Stock solution to keep at the bench is 10 mM 
For standards, dilute and aliquot of 10 mM to make 1 mM and then dilute the 1mM to 
make 0.1mM. Use the 1mM and 0.1mM stock solutions to make standards 











Add 600 µl ashing buffer to samples and standards, vortex well 
Put samples in cold heating block in the hood, then set it to 160°C for O/N (16-24 hrs) 
 
Day 2 
Prepare fresh ascorbic acid (9%) and ammonium molybdate (0.9%) 
**1.8 g Ascorbic acid in 20 mL ddH2O 
**225 mg ammonium molybdate in 25 mL 
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Turn on water bath 45°C 
Add 0.9 mL ddH2O, vortex well 
Add 500 µl 0.9% ammonium molybdate, vortex well 
Add 200µl 9% ascorbic acid, vortex 
Incubate in water bath at 45°C for 30 minutes (check every 10 minutes for color 
development, if purple color develops before the 30 minutes, take the samples out of the 
water bath) 
Add 200µl of each sample and standard per well in a 96 well plate and read at 600 nm 
**To calculate amount of phosphates from the colorimetric readings, make linear curve 
from the standards, using the equation, plug and chug. The value you get, multiple by 4 
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